antiatherosclerotic agent - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	antiatherosclerotic agent	go back to main search page
Accession:	CHEBI:145947	browse the term
Definition:	A cardiovascular drug that prevents atherosclerosis (a disease in which the inside of an artery narrows due to the build up of plaque). Compare with antiatherogenic agent.
Synonyms:	related_synonym:	anti-atherosclerotic agent; anti-atherosclerotic agents; anti-atherosclerotic drug; anti-atherosclerotic drugs; antiatherosclerotic agents; antiatherosclerotic drug; antiatherosclerotic drugs

show annotations for term's descendants Sort by:
Rat (1694) Mouse (1945) Human (1706) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (5) Green Monkey (0) Naked Mole-rat (0) All
Genes (1945)

baicalin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions
increases expression

baicalin results in increased expression of and results in increased activity of ACHE protein
baicalin results in increased expression of ACHE mRNA

NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728

G

aryl-hydrocarbon receptor

increases activity

baicalin results in increased activity of AHR protein

PMID:17869316 PMID:26204831

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

allograft inflammatory factor 1

multiple interactions

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein]

NCBI chr17:35,389,967...35,394,977
Ensembl chr17:35,389,967...35,395,044

G

albumin

multiple interactions

baicalin inhibits the reaction [Arsenic Trioxide results in decreased expression of ALB protein]

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

arachidonate 5-lipoxygenase

multiple interactions

baicalin inhibits the reaction [Hydrogen Peroxide affects the localization of and results in increased activity of ALOX5 protein]

NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139

G

angiopoietin 1

multiple interactions

baicalin inhibits the reaction [Streptozocin results in decreased expression of ANGPT1 mRNA]

NCBI chr15:42,288,063...42,540,373
Ensembl chr15:42,288,119...42,540,373

G

activating transcription factor 2

multiple interactions

baicalin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of ATF2 protein]

NCBI chr 2:73,646,853...73,723,094
Ensembl chr 2:73,646,853...73,722,983

G

BCL2-associated X protein

increases expression
multiple interactions

baicalin results in increased expression of BAX protein
baicalin affects the reaction [Rotenone results in increased expression of BAX mRNA]; baicalin inhibits the reaction [Rotenone results in increased expression of BAX protein]
baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX protein]; baicalin inhibits the reaction [Gentamicins results in increased expression of BAX mRNA]; baicalin inhibits the reaction [Gentamicins results in increased expression of BAX protein]
baicalin inhibits the reaction [Rotenone affects the expression of BAX protein]

PMID:21457722 PMID:25423838 PMID:31021006 PMID:34333357 PMID:35088608 More...

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

multiple interactions
decreases expression

baicalin inhibits the reaction [Rotenone affects the expression of BCL2 protein]
baicalin affects the reaction [Rotenone results in decreased expression of BCL2 mRNA]; baicalin inhibits the reaction [Rotenone results in decreased expression of BCL2 protein]
baicalin results in decreased expression of BCL2 protein
baicalin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; baicalin inhibits the reaction [Gentamicins results in decreased expression of BCL2 mRNA]; baicalin inhibits the reaction [Gentamicins results in decreased expression of BCL2 protein]

PMID:25423838 PMID:31021006 PMID:34333357 PMID:35088608 PMID:36446982

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

caspase 1

multiple interactions

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP1 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]]

NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290

G

caspase 3

multiple interactions

baicalin inhibits the reaction [Rotenone affects the expression of CASP3 protein]
baicalin affects the reaction [Rotenone results in decreased activity of CASP3 protein]
baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein]; baicalin inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein]

PMID:25423838 PMID:31021006 PMID:34333357 PMID:35088608 PMID:36446982

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

catalase

multiple interactions

baicalin inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein]

PMID:34333357 PMID:35088608

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

cyclin A2

decreases expression

baicalin results in decreased expression of CCNA2 protein

NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299

G

cyclin D1

increases expression
decreases expression
multiple interactions

baicalin results in increased expression of CCND1 mRNA
baicalin results in decreased expression of CCND1 protein
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of CCND1 mRNA]

PMID:19160421 PMID:21457722

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

collagen, type I, alpha 2

multiple interactions

baicalin inhibits the reaction [TGFB1 protein results in increased expression of COL1A2 mRNA]

NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A1 mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A1 protein]; baicalin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
baicalin results in increased expression of CYP1A1 mRNA; baicalin results in increased expression of CYP1A1 protein

PMID:18451504 PMID:26204831

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
increases expression

3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A2 mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A2 protein]
resveratrol inhibits the reaction [baicalin results in increased expression of CYP1A2 mRNA]; resveratrol inhibits the reaction [baicalin results in increased expression of CYP1A2 protein]
baicalin results in increased expression of CYP1A2 mRNA; baicalin results in increased expression of CYP1A2 protein

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

epidermal growth factor

multiple interactions

baicalin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; baicalin inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein]

NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965

G

epidermal growth factor receptor

multiple interactions

baicalin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]

NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158

G

ELK1, member of ETS oncogene family

multiple interactions

baicalin inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein]

NCBI chr X:20,799,634...20,816,847
Ensembl chr X:20,799,634...20,816,847

G

endoplasmic reticulum to nucleus signalling 1

multiple interactions

baicalin inhibits the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein]

NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678

G

forkhead box A2

decreases expression

baicalin results in decreased expression of FOXA2 mRNA; baicalin results in decreased expression of FOXA2 protein

NCBI chr 2:147,884,797...147,888,889
Ensembl chr 2:147,884,797...147,888,889

G

glutamic-oxaloacetic transaminase 1, soluble

multiple interactions

baicalin inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GOT1 protein]

NCBI chr19:43,488,191...43,514,743
Ensembl chr19:43,488,191...43,513,044

G

glutamic pyruvic transaminase, soluble

multiple interactions

baicalin inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GPT protein]
baicalin inhibits the reaction [Arsenic Trioxide results in increased activity of GPT protein]

PMID:15645217 PMID:35088608

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

hes family bHLH transcription factor 1

increases expression
multiple interactions

baicalin results in increased expression of HES1 mRNA
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HES1 mRNA]

NCBI chr16:29,883,259...29,886,614
Ensembl chr16:29,883,202...29,886,614

G

hairy/enhancer-of-split related with YRPW motif 1

increases expression
multiple interactions

baicalin results in increased expression of HEY1 mRNA
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY1 mRNA]

NCBI chr 3:8,728,419...8,732,098
Ensembl chr 3:8,728,419...8,732,316

G

hairy/enhancer-of-split related with YRPW motif 2

multiple interactions
increases expression

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY2 mRNA]

NCBI chr10:30,708,355...30,718,779
Ensembl chr10:30,708,355...30,718,797

G

heme oxygenase 1

multiple interactions
increases expression

[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HMOX1 protein]; baicalin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 mRNA]; baicalin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein]
baicalin results in increased expression of HMOX1 mRNA; baicalin results in increased expression of HMOX1 protein

PMID:16824337 PMID:18187930 PMID:38016618

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

HNF1 homeobox A

multiple interactions
decreases expression

baicalin inhibits the reaction [HNF4A protein binds to HNF1A promoter]; HNF1A protein promotes the reaction [baicalin results in decreased secretion of Hepatitis B Surface Antigens]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A mRNA]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A protein]
baicalin results in decreased expression of HNF1A mRNA; baicalin results in decreased expression of HNF1A protein

NCBI chr 5:115,087,039...115,109,121
Ensembl chr 5:115,087,039...115,109,153

G

hepatic nuclear factor 4, alpha

multiple interactions
decreases expression

baicalin inhibits the reaction [HNF4A protein binds to HNF1A promoter]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A mRNA]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A protein]; HNF4A protein promotes the reaction [baicalin results in decreased secretion of Hepatitis B Surface Antigens]
baicalin results in decreased expression of HNF4A protein
baicalin results in decreased expression of HNF4A mRNA; baicalin results in decreased expression of HNF4A protein

NCBI chr 2:163,348,731...163,414,827
Ensembl chr 2:163,348,728...163,414,830

G

heat shock protein 1

multiple interactions

baicalin inhibits the reaction [Streptozocin results in increased phosphorylation of HSPB1 protein]

NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417

G

interleukin 1 beta

multiple interactions

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein]; baicalin inhibits the reaction [Palmitic Acid results in increased secretion of IL1B protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]]
baicalin inhibits the reaction [Rotenone results in increased expression of IL1B protein]

PMID:29031535 PMID:35088608 PMID:36446982 PMID:38016618

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

decreases expression
multiple interactions

baicalin results in decreased expression of IL6 mRNA; baicalin results in decreased expression of IL6 protein
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL6 mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of IL6 protein]; baicalin inhibits the reaction [Palmitic Acid results in increased secretion of IL6 protein]

PMID:22019745 PMID:29031535 PMID:34333357 PMID:35088608 PMID:38016618

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

insulin I

multiple interactions

baicalin inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]

NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914

G

integrin alpha 4

multiple interactions

baicalin inhibits the reaction [ITGA4 protein results in increased expression of KDR protein]; baicalin inhibits the reaction [ITGA4 protein results in increased expression of VEGFA protein]

NCBI chr 2:79,084,767...79,163,458
Ensembl chr 2:79,085,770...79,163,467

G

Janus kinase 2

multiple interactions

baicalin promotes the reaction [Arsenic Trioxide results in increased phosphorylation of JAK2 protein]

NCBI chr19:29,229,006...29,290,495
Ensembl chr19:29,229,228...29,290,480

G

kinase insert domain protein receptor

multiple interactions

baicalin inhibits the reaction [ITGA4 protein results in increased expression of KDR protein]

NCBI chr 5:76,093,487...76,139,880
Ensembl chr 5:76,093,487...76,139,118

G

kelch-like ECH-associated protein 1

multiple interactions

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KEAP1 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in decreased expression of KEAP1 protein]

NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657

G

mitogen-activated protein kinase 1

multiple interactions

baicalin inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK1 protein]

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions

baicalin inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK3 protein]

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

myeloid differentiation primary response gene 88

decreases expression

baicalin results in decreased expression of MYD88 protein

NCBI chr 9:119,165,000...119,169,084
Ensembl chr 9:119,165,000...119,170,477

G

nuclear factor, erythroid derived 2, like 2

multiple interactions

[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] affects the localization of NFE2L2 protein; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]; baicalin inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased ubiquitination of NFE2L2 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; baicalin promotes the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]]

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

increases expression

baicalin results in increased expression of NFKBIA protein

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

NLR family, pyrin domain containing 3

multiple interactions

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NLRP3 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]; baicalin inhibits the reaction [Palmitic Acid results in increased expression of NLRP3 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]]

PMID:29031535 PMID:38016618

NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782

G

nitric oxide synthase 2, inducible

multiple interactions
decreases expression

baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 mRNA]; baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]
baicalin results in decreased expression of NOS2 mRNA; baicalin results in decreased expression of NOS2 protein
baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; mifobate inhibits the reaction [baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]

PMID:18187930 PMID:22019745 PMID:24312512

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

notch 1

increases activity
increases expression

baicalin results in increased activity of NOTCH1 protein
baicalin results in increased expression of NOTCH1 mRNA

NCBI chr 2:26,347,914...26,393,834
Ensembl chr 2:26,347,915...26,406,675

G

nuclear receptor subfamily 1, group H, member 3

increases expression

Baicalin increases expression of NR1H3 mRNA and protein in foam cells

RGD

NCBI chr 2:91,014,406...91,033,189
Ensembl chr 2:91,014,406...91,033,179

G

pyruvate kinase, muscle

increases activity

baicalin results in increased activity of PKM protein

NCBI chr 9:59,563,859...59,586,655
Ensembl chr 9:59,563,651...59,586,658

G

peroxisome proliferator activated receptor gamma

multiple interactions

baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased phosphorylation of and results in decreased activity of PPARG protein]

NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360

G

proline rich membrane anchor 1

increases expression

baicalin results in increased expression of PRIMA1 mRNA

NCBI chr12:103,160,712...103,208,967
Ensembl chr12:103,163,167...103,208,409

G

prostaglandin-endoperoxide synthase 2

decreases expression

baicalin results in decreased expression of PTGS2 mRNA; baicalin results in decreased expression of PTGS2 protein

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

PYD and CARD domain containing

multiple interactions

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]]

NCBI chr 7:127,590,545...127,593,039
Ensembl chr 7:127,588,880...127,593,039

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

baicalin affects the localization of and results in decreased expression of RELA protein
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of RELA protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of and results in increased phosphorylation of RELA protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]]

PMID:22019745 PMID:34333357 PMID:38016618

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

synuclein, alpha

multiple interactions

[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] affects the localization of NFE2L2 protein; [baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL6 mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of TNF mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]; baicalin inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased ubiquitination of NFE2L2 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in decreased expression of KEAP1 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; baicalin promotes the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]]

NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839

G

signal transducer and activator of transcription 3

multiple interactions

baicalin promotes the reaction [Arsenic Trioxide results in increased phosphorylation of STAT3 protein]

NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366

G

TEK receptor tyrosine kinase

multiple interactions

baicalin inhibits the reaction [Streptozocin results in decreased expression of TEK mRNA]

NCBI chr 4:94,627,322...94,763,213
Ensembl chr 4:94,627,526...94,763,213

G

transcription factor A, mitochondrial

decreases expression
multiple interactions

baicalin results in decreased expression of TFAM mRNA
baicalin inhibits the reaction [Rotenone results in decreased expression of TFAM mRNA]

NCBI chr10:71,061,298...71,074,157
Ensembl chr10:71,061,294...71,074,110

G

transforming growth factor, beta 1

multiple interactions

baicalin inhibits the reaction [Streptozocin results in decreased expression of TGFB1 mRNA]; baicalin inhibits the reaction [TGFB1 protein results in increased expression of COL1A2 mRNA]

PMID:19474275 PMID:34414639

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

tyrosine hydroxylase

multiple interactions

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TH protein]

NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865

G

toll-like receptor 4

decreases expression
multiple interactions

baicalin results in decreased expression of TLR4 protein
baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of TLR4 protein]
baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 protein]

PMID:22019745 PMID:24312512 PMID:34333357

NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521

G

tumor necrosis factor

multiple interactions
decreases expression

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of TNF mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]; baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]
baicalin results in decreased expression of TNF mRNA; baicalin results in decreased expression of TNF protein
baicalin inhibits the reaction [Paraquat results in increased expression of TNF protein]

PMID:16824337 PMID:18187930 PMID:22019745 PMID:34333357 PMID:35088608 More...

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

transformation related protein 53

increases expression

baicalin results in increased expression of TP53 protein

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

thioredoxin interacting protein

multiple interactions

baicalin inhibits the reaction [Palmitic Acid results in increased expression of TXNIP protein]; dorsomorphin inhibits the reaction [baicalin inhibits the reaction [Palmitic Acid results in increased expression of TXNIP protein]]

NCBI chr 3:96,465,273...96,469,173
Ensembl chr 3:96,465,273...96,469,199

G

ubiquitin specific peptidase 27, X chromosome

multiple interactions

baicalin inhibits the reaction [Streptozocin results in increased expression of USP27X protein]

NCBI chr X:7,238,830...7,242,069
Ensembl chr X:7,237,513...7,242,069

G

vascular endothelial growth factor A

multiple interactions

baicalin inhibits the reaction [ITGA4 protein results in increased expression of VEGFA protein]

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

G

vascular endothelial growth factor C

multiple interactions

baicalin inhibits the reaction [Streptozocin results in decreased expression of VEGFC mRNA]

NCBI chr 8:54,530,567...54,639,489
Ensembl chr 8:54,530,641...54,640,131

G

xanthine dehydrogenase

multiple interactions

baicalin inhibits the reaction [[Biological Products co-treated with potassium oxonate] results in increased activity of XDH protein]

NCBI chr17:74,190,890...74,257,191
Ensembl chr17:74,190,890...74,257,191

dextran sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

4-aminobutyrate aminotransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABAT mRNA

NCBI chr16:8,331,293...8,439,432
Ensembl chr16:8,331,293...8,439,432

G

ATP-binding cassette, sub-family A member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA1 mRNA

NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895

G

ATP-binding cassette, sub-family A member 17

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA17 mRNA

NCBI chr17:24,483,231...24,570,079
Ensembl chr17:24,483,233...24,570,042

G

ATP-binding cassette, sub-family B member 11

decreases expression

Dextran Sulfate results in decreased expression of ABCB11 mRNA; Dextran Sulfate results in decreased expression of ABCB11 protein

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

ATP-binding cassette, sub-family B member 1A

multiple interactions
decreases expression
increases response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1A mRNA; ABCB1A protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
Dextran Sulfate results in decreased expression of ABCB1A mRNA
ABCB1A gene mutant form results in increased susceptibility to Dextran Sulfate

PMID:29950665 PMID:30102254 PMID:30701287 PMID:35093514

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

ATP-binding cassette, sub-family B member 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1B mRNA; ABCB1B protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:29950665 PMID:30701287

NCBI chr 5:8,848,147...8,916,314
Ensembl chr 5:8,848,147...8,916,315

G

ATP-binding cassette, sub-family B member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB4 mRNA

NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231

G

ATP-binding cassette, sub-family B member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB6 mRNA

NCBI chr 1:75,148,284...75,157,066
Ensembl chr 1:75,148,361...75,157,036

G

ATP-binding cassette, sub-family C member 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC10 mRNA

NCBI chr17:46,614,146...46,638,954
Ensembl chr17:46,614,147...46,639,278

G

ATP-binding cassette, sub-family member 2

decreases expression
multiple interactions
affects response to substance

Dextran Sulfate results in decreased expression of ABCC2 mRNA; Dextran Sulfate results in decreased expression of ABCC2 protein
ABCC2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
ABCC2 protein affects the susceptibility to Dextran Sulfate

PMID:27580383 PMID:30701287

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

G

ATP-binding cassette, sub-family C member 3

decreases expression
affects response to substance
multiple interactions

Dextran Sulfate results in decreased expression of ABCC3 mRNA; Dextran Sulfate results in decreased expression of ABCC3 protein
ABCC3 protein affects the susceptibility to Dextran Sulfate
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC3 mRNA; ABCC3 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:27580383 PMID:29950665 PMID:30701287

NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823

G

ATP-binding cassette, sub-family C member 4

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ABCC4 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC4 mRNA
Dextran Sulfate results in decreased expression of ABCC4 mRNA; Dextran Sulfate results in decreased expression of ABCC4 protein

PMID:26271895 PMID:27580383 PMID:29950665

NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631

G

ATP-binding cassette, sub-family C member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC5 mRNA

NCBI chr16:20,150,053...20,245,178
Ensembl chr16:20,150,053...20,245,144

G

ATP-binding cassette, sub-family C member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC6 mRNA

NCBI chr 7:45,625,804...45,679,915
Ensembl chr 7:45,616,979...45,679,726

G

ATP-binding cassette, sub-family C member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC9 mRNA

NCBI chr 6:142,533,592...142,648,472
Ensembl chr 6:142,533,588...142,648,041

G

ATP-binding cassette, sub-family F member 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ABCF2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABCF2 protein]

NCBI chr 5:24,770,339...24,782,465
Ensembl chr 5:24,770,343...24,782,465

G

ATP binding cassette subfamily G member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCG1 mRNA

NCBI chr17:31,276,668...31,336,958
Ensembl chr17:31,276,649...31,336,962

G

ATP binding cassette subfamily G member 2 (Junior blood group)

multiple interactions
decreases expression
affects response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCG2 mRNA; ABCG2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
Dextran Sulfate results in decreased expression of ABCG2 mRNA; Dextran Sulfate results in decreased expression of ABCG2 protein
Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]
ABCG2 protein affects the susceptibility to Dextran Sulfate

PMID:29950665 PMID:30701287 PMID:38423481

NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661

G

abl interactor 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ABI1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABI1 protein]

NCBI chr 2:22,830,085...22,930,207
Ensembl chr 2:22,830,085...22,930,253

G

acetyl-Coenzyme A acyltransferase 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1A mRNA

NCBI chr 9:119,170,113...119,179,361
Ensembl chr 9:119,168,742...119,179,365

G

acetyl-Coenzyme A acyltransferase 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1B mRNA

NCBI chr 9:118,977,111...118,986,149
Ensembl chr 9:118,977,091...118,986,161

G

acetyl-CoA acyltransferase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA2 mRNA

NCBI chr18:74,912,283...74,939,278
Ensembl chr18:74,912,268...74,939,279

G

acetyl-Coenzyme A carboxylase alpha

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ACACA protein]

NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477

G

acyl-Coenzyme A dehydrogenase, short chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADS mRNA

NCBI chr 5:115,248,358...115,257,405
Ensembl chr 5:115,248,358...115,257,405

G

acyl-Coenzyme A dehydrogenase, short/branched chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADSB mRNA

NCBI chr 7:131,012,330...131,047,940
Ensembl chr 7:131,012,330...131,050,673

G

angiotensin I converting enzyme

multiple interactions
increases abundance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACE mRNA
dextran sodium sulfate increases abundance of Ace protein in small and large intestine extracellular space

CTD
RGD

PMID:29950665 PMID:26401072

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

G

acetylcholinesterase

multiple interactions
decreases activity

[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of ACHE protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACHE mRNA
Dextran Sulfate results in decreased activity of ACHE protein

PMID:29950665 PMID:31226429 PMID:31807802

NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728

G

atypical chemokine receptor 1 (Duffy blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR1 mRNA

NCBI chr 1:173,159,457...173,161,079
Ensembl chr 1:173,159,453...173,161,317

G

atypical chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR2 mRNA

NCBI chr 9:121,727,421...121,740,177
Ensembl chr 9:121,727,421...121,740,140

G

atypical chemokine receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR3 mRNA

NCBI chr 1:90,131,702...90,143,446
Ensembl chr 1:90,131,702...90,144,473

G

atypical chemokine receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACKR4 mRNA

NCBI chr 9:103,974,881...104,003,842
Ensembl chr 9:103,961,356...104,004,132

G

acyl-CoA synthetase bubblegum family member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSBG2 mRNA

NCBI chr17:57,150,103...57,181,505
Ensembl chr17:57,150,103...57,181,447

G

acyl-CoA synthetase medium-chain family member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACSM1 mRNA

NCBI chr 7:119,217,035...119,261,738
Ensembl chr 7:119,206,249...119,261,738

G

acyl-CoA synthetase medium-chain family member 3

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ACSM3 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACSM3 protein]

NCBI chr 7:119,360,106...119,384,119
Ensembl chr 7:119,360,146...119,386,736

G

acyl-CoA synthetase short-chain family member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS1 mRNA

NCBI chr 2:150,460,031...150,510,160
Ensembl chr 2:150,460,025...150,510,420

G

acyl-CoA synthetase short-chain family member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS2 mRNA

NCBI chr 2:155,359,963...155,404,663
Ensembl chr 2:155,359,868...155,427,644

G

actin-like 6A

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACTL6A protein]

NCBI chr 3:32,762,695...32,781,122
Ensembl chr 3:32,760,447...32,781,122

G

actinin, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN1 mRNA

NCBI chr12:80,214,316...80,307,165
Ensembl chr12:80,214,321...80,307,145

G

actinin alpha 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN2 mRNA

NCBI chr13:12,284,312...12,355,613
Ensembl chr13:12,284,312...12,355,641

G

actin related protein 2

decreases expression

Dextran Sulfate results in decreased expression of ACTR2 protein

NCBI chr11:20,012,304...20,062,951
Ensembl chr11:20,012,304...20,062,913

G

ARP3 actin-related protein 3

decreases expression

Dextran Sulfate results in decreased expression of ACTR3 protein

NCBI chr 1:125,320,642...125,363,464
Ensembl chr 1:125,320,642...125,363,464

G

activin A receptor, type 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACVR1 mRNA

NCBI chr 2:58,336,450...58,456,840
Ensembl chr 2:58,278,656...58,457,169

G

aminoacylase 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ACY1 protein

NCBI chr 9:106,310,180...106,315,594
Ensembl chr 9:106,310,180...106,315,518

G

adenosine deaminase

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ADA protein]

NCBI chr 2:163,565,703...163,592,154
Ensembl chr 2:163,568,504...163,592,159

G

a disintegrin and metallopeptidase domain 17

multiple interactions
increases expression
affects response to substance

ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IFNG protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL17A protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL1B protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of ADAM17 mRNA]
ADAM17 protein affects the susceptibility to Dextran Sulfate

NCBI chr12:21,373,510...21,423,633
Ensembl chr12:21,373,510...21,423,633

G

ADAM metallopeptidase with thrombospondin type 1 motif 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS1 mRNA

NCBI chr16:85,590,715...85,600,001
Ensembl chr16:85,590,715...85,600,001

G

ADAM metallopeptidase with thrombospondin type 1 motif 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS14 mRNA

NCBI chr10:61,032,886...61,109,447
Ensembl chr10:61,032,891...61,109,217

G

ADAM metallopeptidase with thrombospondin type 1 motif 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS2 mRNA

NCBI chr11:50,492,912...50,698,400
Ensembl chr11:50,492,911...50,698,400

G

ADAM metallopeptidase with thrombospondin type 1 motif 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS4 mRNA

NCBI chr 1:171,077,698...171,089,836
Ensembl chr 1:171,077,990...171,088,206

G

ADAM metallopeptidase with thrombospondin type 1 motif 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS5 mRNA

NCBI chr16:85,655,045...85,698,013
Ensembl chr16:85,653,061...85,698,716

G

adenylate cyclase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY2 mRNA

NCBI chr13:68,768,162...69,147,719
Ensembl chr13:68,768,162...69,147,660

G

adenylate cyclase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY4 mRNA

NCBI chr14:56,006,513...56,021,552
Ensembl chr14:56,006,514...56,021,552

G

adenylate cyclase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCY6 mRNA

NCBI chr15:98,484,982...98,508,119
Ensembl chr15:98,487,854...98,507,957

G

adenylate cyclase 7

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY7 mRNA
Dextran Sulfate results in decreased expression of ADCY7 mRNA

PMID:29950665 PMID:35093514

NCBI chr 8:88,998,818...89,056,593
Ensembl chr 8:88,999,031...89,056,590

G

adenylate cyclase activating polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCYAP1 mRNA

NCBI chr17:93,506,448...93,513,967
Ensembl chr17:93,506,445...93,513,965

G

adenylate cyclase activating polypeptide 1 receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCYAP1R1 mRNA

NCBI chr 6:55,428,486...55,478,440
Ensembl chr 6:55,428,963...55,478,436

G

adhesion G protein-coupled receptor A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRA2 mRNA

NCBI chr 8:27,575,546...27,613,464
Ensembl chr 8:27,575,611...27,613,464

G

adhesion G protein-coupled receptor B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADGRB1 mRNA

NCBI chr15:74,388,045...74,461,314
Ensembl chr15:74,388,044...74,461,314

G

adhesion G protein-coupled receptor E1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ADGRE1 protein
flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of ADGRE1 protein]

NCBI chr17:57,665,650...57,790,527
Ensembl chr17:57,665,691...57,790,527

G

adhesion G protein-coupled receptor E5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRE5 mRNA

NCBI chr 8:84,449,874...84,467,812
Ensembl chr 8:84,449,880...84,467,955

G

adhesion G protein-coupled receptor F1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF1 mRNA

NCBI chr17:43,581,174...43,636,767
Ensembl chr17:43,581,220...43,635,628

G

adhesion G protein-coupled receptor F5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF5 mRNA

NCBI chr17:43,671,225...43,770,448
Ensembl chr17:43,671,342...43,770,448

G

alcohol dehydrogenase 1 (class I)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADH1 mRNA

NCBI chr 3:137,983,346...137,996,459
Ensembl chr 3:137,966,752...137,996,459

G

alcohol dehydrogenase 5 (class III), chi polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADH5 mRNA

NCBI chr 3:138,142,961...138,161,260
Ensembl chr 3:138,148,854...138,161,260

G

adrenomedullin

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADM mRNA
Dextran Sulfate results in increased expression of ADM mRNA

PMID:29950665 PMID:35093514

NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027

G

adenosine A2a receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA2A mRNA

NCBI chr10:75,152,711...75,170,626
Ensembl chr10:75,152,711...75,170,618

G

adenosine A2b receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ADORA2B mRNA

NCBI chr11:62,139,810...62,157,278
Ensembl chr11:62,139,810...62,157,279

G

adenosine A3 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA3 mRNA

NCBI chr 3:105,811,737...105,816,244
Ensembl chr 3:105,778,174...105,816,242

G

adrenergic receptor, alpha 2a

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADRA2A mRNA

NCBI chr19:54,033,690...54,037,413
Ensembl chr19:54,032,582...54,037,413

G

adrenergic receptor, beta 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ADRB2 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADRB2 mRNA

PMID:26271895 PMID:29950665

NCBI chr18:62,310,784...62,313,052
Ensembl chr18:62,310,887...62,313,030

G

angiotensinogen

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AGT mRNA
Dextran Sulfate results in decreased expression of AGT mRNA

PMID:29950665 PMID:35093514

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

G

AHNAK nucleoprotein

decreases expression

Dextran Sulfate results in decreased expression of AHNAK mRNA

NCBI chr19:8,966,640...9,054,299
Ensembl chr19:8,966,648...9,054,278

G

aryl-hydrocarbon receptor

increases response to substance
multiple interactions

AHR gene mutant form results in increased susceptibility to Dextran Sulfate
AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of LCN2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

alpha hemoglobin stabilizing protein

decreases expression

Dextran Sulfate results in decreased expression of AHSP protein

NCBI chr 7:127,902,016...127,902,926
Ensembl chr 7:127,901,969...127,902,930

G

adenylate kinase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of AK1 protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of AK1 protein

NCBI chr 2:32,511,770...32,525,070
Ensembl chr 2:32,511,770...32,525,070

G

A kinase anchor protein 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP12 mRNA

NCBI chr10:4,216,329...4,309,471
Ensembl chr10:4,216,380...4,309,470

G

A kinase anchor protein 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP5 mRNA

NCBI chr12:76,371,652...76,380,925
Ensembl chr12:76,371,665...76,380,927

G

aldo-keto reductase family 1 member B

decreases expression
multiple interactions
increases expression

Dextran Sulfate results in decreased expression of AKR1B1 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKR1B1 mRNA
Dextran Sulfate results in increased expression of AKR1B1 mRNA

PMID:29950665 PMID:35093514 PMID:35999755

NCBI chr 6:34,280,865...34,294,424
Ensembl chr 6:34,279,369...34,294,413

G

aldo-keto reductase family 1, member C12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C12 mRNA

NCBI chr13:4,318,171...4,329,398
Ensembl chr13:4,318,175...4,329,432

G

aldo-keto reductase family 1, member C13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C13 mRNA

NCBI chr13:4,241,167...4,255,601
Ensembl chr13:4,241,149...4,255,595

G

aldo-keto reductase family 1, member C14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C14 mRNA

NCBI chr13:4,099,015...4,140,569
Ensembl chr13:4,099,011...4,140,688

G

aldo-keto reductase family 1, member C18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C18 mRNA

NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653

G

aldo-keto reductase family 1, member C19

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C19 mRNA

NCBI chr13:4,283,499...4,298,360
Ensembl chr13:4,278,699...4,302,842

G

thymoma viral proto-oncogene 1

multiple interactions

[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein]
banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]

PMID:26262998 PMID:36806191

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

albumin

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ALB protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALB mRNA

PMID:29950665 PMID:35999755

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

aldehyde dehydrogenase family 1, subfamily A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1A1 mRNA

NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829

G

aldehyde dehydrogenase family 1, subfamily A7

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1A7 mRNA
Dextran Sulfate results in decreased expression of ALDH1A7 mRNA

PMID:29950665 PMID:35093514

NCBI chr19:20,670,318...20,704,920
Ensembl chr19:20,670,317...20,704,926

G

aldehyde dehydrogenase 1 family, member B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1B1 mRNA

NCBI chr 4:45,799,022...45,804,608
Ensembl chr 4:45,799,022...45,804,604

G

aldehyde dehydrogenase 2, mitochondrial

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH2 mRNA

NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887

G

aldehyde dehydrogenase family 3, subfamily A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH3A2 mRNA

NCBI chr11:61,114,240...61,158,267
Ensembl chr11:61,114,243...61,158,290

G

aldehyde dehydrogenase family 7, member A1

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ALDH7A1 protein]

NCBI chr18:56,657,794...56,706,112
Ensembl chr18:56,642,759...56,706,023

G

aldolase C, fructose-bisphosphate

decreases expression

Dextran Sulfate results in decreased expression of ALDOA protein; Dextran Sulfate results in decreased expression of ALDOC mRNA

PMID:35093514 PMID:35999755

NCBI chr11:78,213,899...78,218,607
Ensembl chr11:78,213,794...78,218,607

G

arachidonate 12-lipoxygenase

decreases expression

Dextran Sulfate results in decreased expression of ALOX12 protein

NCBI chr11:70,132,283...70,146,206
Ensembl chr11:70,132,283...70,146,179

G

arachidonate 12-lipoxygenase, 12R type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX12B mRNA

NCBI chr11:69,047,898...69,060,617
Ensembl chr11:69,047,815...69,060,618

G

arachidonate 5-lipoxygenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5 mRNA

NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139

G

arachidonate 5-lipoxygenase activating protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5AP mRNA

NCBI chr 5:149,201,814...149,224,963
Ensembl chr 5:149,201,577...149,224,963

G

alkaline phosphatase, liver/bone/kidney

multiple interactions
increases activity

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALPL mRNA
Dextran Sulfate results in increased activity of ALPL protein

PMID:29950665 PMID:30489199

NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695

G

angiopoietin 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANGPT4 mRNA

NCBI chr 2:151,753,127...151,787,257
Ensembl chr 2:151,753,130...151,787,257

G

angiopoietin-like 4

increases expression

Dextran Sulfate results in increased expression of ANGPTL4 mRNA

NCBI chr17:33,993,874...34,000,549
Ensembl chr17:33,992,724...34,000,804

G

anoctamin 1, calcium activated chloride channel

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO1 mRNA

NCBI chr 7:144,142,286...144,305,762
Ensembl chr 7:144,142,286...144,305,711

G

anoctamin 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO10 mRNA

NCBI chr 9:122,004,958...122,123,440
Ensembl chr 9:122,004,940...122,123,489

G

anoctamin 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO6 mRNA

NCBI chr15:95,688,724...95,873,353
Ensembl chr15:95,688,724...95,872,632

G

anoctamin 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO7 mRNA

NCBI chr 1:93,301,518...93,332,026
Ensembl chr 1:93,301,652...93,332,025

G

anoctamin 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO9 mRNA

NCBI chr 7:140,681,125...140,697,719
Ensembl chr 7:140,681,125...140,697,719

G

annexin A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANXA1 mRNA

NCBI chr19:20,350,798...20,368,035
Ensembl chr19:20,350,792...20,368,308

G

annexin A4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANXA4 mRNA

NCBI chr 6:86,713,822...86,770,616
Ensembl chr 6:86,713,822...86,770,566

G

adaptor-related protein complex AP-1, mu subunit 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AP1M1 mRNA

NCBI chr 8:72,993,857...73,011,230
Ensembl chr 8:72,993,862...73,011,229

G

adaptor protein complex AP-1, sigma 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of AP1S1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of AP1S1 protein]

NCBI chr 5:137,063,852...137,074,917
Ensembl chr 5:137,063,847...137,074,989

G

APC, WNT signaling pathway regulator

affects response to substance
multiple interactions

APC affects the susceptibility to Dextran Sulfate; APC protein affects the susceptibility to Dextran Sulfate
[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; PDE4B protein affects the reaction [APC protein affects the susceptibility to Dextran Sulfate]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein]

PMID:16049979 PMID:26262998 PMID:30188895

NCBI chr18:34,353,350...34,455,243
Ensembl chr18:34,353,977...34,455,605

G

amyloid P component, serum

increases expression

Dextran Sulfate results in increased expression of APCS protein

NCBI chr 1:172,721,528...172,722,516
Ensembl chr 1:172,721,528...172,722,608

G

apelin

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APLN mRNA
Dextran Sulfate results in decreased expression of APLN mRNA

PMID:29950665 PMID:35093514

NCBI chr X:47,114,023...47,123,730
Ensembl chr X:47,114,023...47,123,730

G

apolipoprotein A-II

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of APOA2 protein

NCBI chr 1:171,049,133...171,053,948
Ensembl chr 1:171,052,623...171,053,948

G

apolipoprotein A-IV

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOA4 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of APOA4 protein]

PMID:32272095 PMID:35999755

NCBI chr 9:46,152,142...46,154,756
Ensembl chr 9:46,151,994...46,154,757

G

apolipoprotein B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of APOB mRNA

NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835

G

apolipoprotein C2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOC2 protein

NCBI chr 7:19,405,504...19,411,866
Ensembl chr 7:19,405,504...19,411,866

G

apolipoprotein E

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of APOE protein]

NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113

G

amyloid beta precursor protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APP mRNA

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

G

aquaporin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP1 mRNA

NCBI chr 6:55,313,284...55,325,540
Ensembl chr 6:55,313,417...55,325,540

G

aquaporin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP11 mRNA

NCBI chr 7:97,375,586...97,387,454
Ensembl chr 7:97,373,213...97,387,496

G

aquaporin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP2 mRNA

NCBI chr15:99,476,937...99,482,426
Ensembl chr15:99,476,936...99,482,428

G

aquaporin 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP3 mRNA

NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183

G

aquaporin 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP8 mRNA

NCBI chr 7:123,061,517...123,067,226
Ensembl chr 7:123,061,514...123,067,227

G

aquaporin 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP9 mRNA

NCBI chr 9:71,017,941...71,075,170
Ensembl chr 9:71,017,941...71,075,964

G

androgen receptor

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AR mRNA
Dextran Sulfate results in increased expression of AR mRNA

PMID:27920257 PMID:29950665

NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821

G

ARF GTPase 3

decreases expression

Dextran Sulfate results in decreased expression of ARF3 protein

NCBI chr15:98,635,505...98,660,999
Ensembl chr15:98,634,515...98,661,095

G

arginase, liver

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein]
Dextran Sulfate results in decreased expression of ARG1 mRNA; Dextran Sulfate results in decreased expression of ARG1 protein

PMID:25026504 PMID:38164749

NCBI chr10:24,791,105...24,803,368
Ensembl chr10:24,791,119...24,803,382

G

Rho GTPase activating protein 1

decreases expression

Dextran Sulfate results in decreased expression of ARHGAP1 protein

NCBI chr 2:91,480,463...91,502,670
Ensembl chr 2:91,480,205...91,502,671

G

Rho GTPase activating protein 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP15 mRNA

NCBI chr 2:43,638,786...44,285,965
Ensembl chr 2:43,638,836...44,285,965

G

Rho GTPase activating protein 20

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP20 mRNA

NCBI chr 9:51,676,651...51,765,158
Ensembl chr 9:51,676,637...51,765,156

G

Rho GTPase activating protein 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP25 mRNA

NCBI chr 6:87,435,526...87,510,241
Ensembl chr 6:87,435,527...87,510,241

G

Rho GTPase activating protein 40

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP40 mRNA

NCBI chr 2:158,354,682...158,392,786
Ensembl chr 2:158,354,716...158,392,682

G

Rho GDP dissociation inhibitor alpha

decreases expression

Dextran Sulfate results in decreased expression of ARHGDIA protein

NCBI chr11:120,468,925...120,472,450
Ensembl chr11:120,468,930...120,472,450

G

Rho, GDP dissociation inhibitor beta

increases expression
decreases expression
multiple interactions

Dextran Sulfate results in increased expression of ARHGDIB mRNA
Dextran Sulfate results in decreased expression of ARHGDIB protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGDIB mRNA

PMID:23894361 PMID:29950665 PMID:35999755

NCBI chr 6:136,900,653...136,918,895
Ensembl chr 6:136,900,653...136,918,897

G

Rho guanine nucleotide exchange factor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF1 mRNA

NCBI chr 7:24,601,762...24,626,019
Ensembl chr 7:24,602,337...24,626,019

G

Rho guanine nucleotide exchange factor 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGEF12 mRNA

NCBI chr 9:42,875,138...43,017,069
Ensembl chr 9:42,875,138...43,018,534

G

Rac/Cdc42 guanine nucleotide exchange factor 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF6 mRNA

NCBI chr X:56,276,845...56,384,119
Ensembl chr X:56,276,845...56,384,089

G

ADP-ribosylation factor-like 3

increases expression

Dextran Sulfate results in increased expression of ARL3 mRNA

NCBI chr19:46,519,548...46,561,621
Ensembl chr19:46,519,535...46,561,637

G

ADP-ribosylation factor-like 9

increases expression

Dextran Sulfate results in increased expression of ARL9 mRNA

NCBI chr 5:77,146,054...77,158,806
Ensembl chr 5:77,151,902...77,158,453

G

actin related protein 2/3 complex, subunit 2

decreases expression

Dextran Sulfate results in decreased expression of ARPC2 protein

NCBI chr 1:74,275,656...74,307,368
Ensembl chr 1:74,275,243...74,307,368

G

actin related protein 2/3 complex, subunit 3

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ARPC3 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ARPC3 protein

NCBI chr 5:122,529,941...122,544,244
Ensembl chr 5:122,529,941...122,552,247

G

actin related protein 2/3 complex, subunit 4

decreases expression

Dextran Sulfate results in decreased expression of ARPC4 protein

NCBI chr 6:113,355,074...113,367,408
Ensembl chr 6:113,355,076...113,367,409

G

arrestin, beta 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ARRB2 mRNA

NCBI chr11:70,323,051...70,331,654
Ensembl chr11:70,323,461...70,331,654

G

arylsulfatase B

decreases expression

Dextran Sulfate results in decreased expression of ARSB mRNA

NCBI chr13:93,908,187...94,079,524
Ensembl chr13:93,908,138...94,079,524

G

ankyrin repeat and SOCS box-containing 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ASB2 mRNA

NCBI chr12:103,287,401...103,322,260
Ensembl chr12:103,287,401...103,322,260

G

acid-sensing ion channel family member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ASIC4 mRNA

NCBI chr 1:75,426,467...75,450,984
Ensembl chr 1:75,427,080...75,450,987

G

argininosuccinate synthetase 1

decreases expression

Dextran Sulfate results in decreased expression of ASS1 mRNA

NCBI chr 2:31,360,282...31,410,682
Ensembl chr 2:31,360,219...31,410,684

G

autophagy related 5

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA]

PMID:27611972 PMID:31676321 PMID:35439472

NCBI chr10:44,144,325...44,240,295
Ensembl chr10:44,144,354...44,240,287

G

autophagy related 7

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]

NCBI chr 6:114,620,075...114,837,565
Ensembl chr 6:114,620,058...114,837,575

G

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase

decreases expression

Dextran Sulfate results in decreased expression of ATIC protein

NCBI chr 1:71,596,315...71,618,562
Ensembl chr 1:71,596,309...71,618,790

G

ATPase, class V, type 10A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP10A mRNA

NCBI chr 7:58,305,896...58,479,783
Ensembl chr 7:58,305,914...58,479,168

G

ATPase, class VI, type 11B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP11B mRNA

NCBI chr 3:35,808,104...35,910,425
Ensembl chr 3:35,808,255...35,910,425

G

ATPase, H+/K+ transporting, nongastric, alpha polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP12A mRNA

NCBI chr14:56,602,525...56,626,008
Ensembl chr14:56,602,525...56,626,007

G

ATPase, Na+/K+ transporting, alpha 1 polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A1 mRNA

NCBI chr 3:101,483,535...101,512,023
Ensembl chr 3:101,483,535...101,512,000

G

ATPase, Na+/K+ transporting, alpha 3 polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A3 mRNA

NCBI chr 7:24,677,592...24,705,338
Ensembl chr 7:24,677,592...24,705,383

G

ATPase, Na+/K+ transporting, alpha 4 polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1A4 mRNA

NCBI chr 1:172,051,075...172,085,991
Ensembl chr 1:172,051,080...172,085,981

G

ATPase, Na+/K+ transporting, beta 1 polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1B1 mRNA

NCBI chr 1:164,264,668...164,285,924
Ensembl chr 1:164,264,678...164,285,924

G

ATPase, Na+/K+ transporting, beta 3 polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1B3 mRNA

NCBI chr 9:96,214,708...96,246,368
Ensembl chr 9:96,214,708...96,246,495

G

ATPase, Ca++ transporting, cardiac muscle, fast twitch 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP2A1 mRNA

NCBI chr 7:126,045,032...126,062,245
Ensembl chr 7:126,045,030...126,062,280

G

ATPase, Ca++ transporting, ubiquitous

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2A3 mRNA

NCBI chr11:72,851,995...72,883,869
Ensembl chr11:72,851,995...72,883,870

G

ATPase, Ca++ transporting, plasma membrane 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2B1 mRNA

NCBI chr10:98,750,243...98,862,005
Ensembl chr10:98,750,268...98,862,005

G

ATPase, Ca++ transporting, type 2C, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ATP2C2 mRNA

NCBI chr 8:120,426,748...120,484,457
Ensembl chr 8:120,426,748...120,484,456

G

ATPase, H+/K+ exchanging, beta polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP4B mRNA

NCBI chr 8:13,436,209...13,446,778
Ensembl chr 8:13,436,205...13,446,825

G

ATPase, H+ transporting, lysosomal V0 subunit A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V0A2 mRNA

NCBI chr 5:124,767,117...124,801,519
Ensembl chr 5:124,766,641...124,801,519

G

ATPase, H+ transporting, lysosomal V0 subunit A4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0A4 mRNA

NCBI chr 6:38,025,418...38,101,521
Ensembl chr 6:38,025,418...38,101,521

G

ATPase, H+ transporting, lysosomal V0 subunit D2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0D2 mRNA

NCBI chr 4:19,876,838...19,922,566
Ensembl chr 4:19,876,841...19,922,605

G

ATPase, H+ transporting, lysosomal V1 subunit E2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V1E2 mRNA

NCBI chr17:87,251,537...87,255,315
Ensembl chr17:87,251,537...87,255,325

G

ATPase, H+ transporting, lysosomal V1 subunit F

increases expression

Dextran Sulfate results in increased expression of ATP6V1F mRNA

NCBI chr 6:29,467,782...29,470,508
Ensembl chr 6:29,467,717...29,470,511

G

ATPase, H+ transporting, lysosomal V1 subunit G3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V1G3 mRNA

NCBI chr 1:138,201,476...138,217,200
Ensembl chr 1:138,201,476...138,217,200

G

ATPase, copper transporting, alpha polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP7A mRNA

NCBI chr X:105,070,830...105,171,766
Ensembl chr X:105,070,882...105,168,532

G

ATPase, class I, type 8B, member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP8B1 mRNA

NCBI chr18:64,662,050...64,794,342
Ensembl chr18:64,662,038...64,794,338

G

ATPase, class I, type 8B, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP8B2 mRNA

NCBI chr 3:89,846,795...89,870,645
Ensembl chr 3:89,846,788...89,870,815

G

arginine vasopressin receptor 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1A mRNA

NCBI chr10:122,284,404...122,289,358
Ensembl chr10:122,284,404...122,289,357

G

arginine vasopressin receptor 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1B mRNA

NCBI chr 1:131,526,908...131,539,740
Ensembl chr 1:131,526,977...131,539,738

G

arginine vasopressin receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AVPR2 mRNA

NCBI chr X:72,935,371...72,938,034
Ensembl chr X:72,935,708...72,939,108

G

axin 2

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein]

NCBI chr11:108,808,687...108,841,609
Ensembl chr11:108,811,175...108,841,609

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of B3GNT3 mRNA

NCBI chr 8:72,144,017...72,155,270
Ensembl chr 8:72,143,400...72,154,433

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of B3GNT7 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of B3GNT7 protein]

NCBI chr 1:86,230,943...86,235,027
Ensembl chr 1:86,230,554...86,235,027

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of B3GNT8 mRNA

NCBI chr 7:25,327,025...25,328,917
Ensembl chr 7:25,326,079...25,334,525

G

bile acid-Coenzyme A: amino acid N-acyltransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BAAT mRNA

NCBI chr 4:49,489,416...49,507,915
Ensembl chr 4:49,489,422...49,506,557

G

BAF nuclear assembly factor 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BANF1 protein]

NCBI chr19:5,414,661...5,416,904
Ensembl chr19:5,414,666...5,417,196

G

B cell scaffold protein with ankyrin repeats 1

increases expression

Dextran Sulfate results in increased expression of BANK1 mRNA

NCBI chr 3:135,759,124...136,031,902
Ensembl chr 3:135,759,124...136,031,827

G

BCL2-associated X protein

multiple interactions
increases expression

[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX mRNA; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX protein; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased cleavage of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]

PMID:24146755 PMID:37209277 PMID:38583725

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

butyrylcholinesterase

multiple interactions
decreases activity

[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of BCHE protein
Dextran Sulfate results in decreased activity of BCHE protein

PMID:31226429 PMID:31807802

NCBI chr 3:73,543,138...73,615,767
Ensembl chr 3:73,543,141...73,615,748

G

B cell leukemia/lymphoma 2

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]

PMID:25449198 PMID:37209277 PMID:38583725

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

B cell leukemia/lymphoma 6

multiple interactions

BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]]

NCBI chr16:23,780,058...23,807,602
Ensembl chr16:23,783,802...23,807,602

G

B cell CLL/lymphoma 7C

increases expression

Dextran Sulfate results in increased expression of BCL7C mRNA

NCBI chr 7:127,260,626...127,307,938
Ensembl chr 7:127,260,628...127,308,105

G

bradykinin receptor, beta 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB1 mRNA

NCBI chr12:105,570,350...105,571,770
Ensembl chr12:105,569,344...105,571,687

G

bradykinin receptor, beta 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB2 mRNA

NCBI chr12:105,529,431...105,561,503
Ensembl chr12:105,529,485...105,561,496

G

beclin 1, autophagy related

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of BECN1 protein; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]
dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]

PMID:27611972 PMID:31676321 PMID:31926917

NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112

G

bestrophin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BEST1 mRNA

NCBI chr19:9,962,536...9,978,997
Ensembl chr19:9,962,538...9,978,997

G

biglycan

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BGN mRNA

NCBI chr X:72,527,207...72,539,542
Ensembl chr X:72,527,208...72,539,539

G

bridging integrator 2

decreases expression

Dextran Sulfate results in decreased expression of BIN2 protein

NCBI chr15:100,538,963...100,567,384
Ensembl chr15:100,538,958...100,567,434

G

baculoviral IAP repeat-containing 5

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]

NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569

G

baculoviral IAP repeat-containing 6

decreases expression

Dextran Sulfate results in decreased expression of BIRC6 mRNA

NCBI chr17:74,835,247...75,010,351
Ensembl chr17:74,835,290...75,010,351

G

bone morphogenetic protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP1 mRNA

NCBI chr14:70,711,998...70,758,280
Ensembl chr14:70,711,998...70,757,674

G

bone morphogenetic protein 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP10 mRNA

NCBI chr 6:87,405,976...87,411,494
Ensembl chr 6:87,405,976...87,414,659

G

bone morphogenetic protein 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP7 mRNA

NCBI chr 2:172,709,805...172,782,114
Ensembl chr 2:172,709,805...172,782,114

G

bone morphogenetic protein receptor, type 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMPR1B mRNA

NCBI chr 3:141,540,230...141,875,335
Ensembl chr 3:141,542,897...141,875,186

G

bone morphogenetic protein receptor type 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BMPR2 mRNA

NCBI chr 1:59,802,721...59,917,240
Ensembl chr 1:59,802,559...59,918,173

G

BPI fold containing family A, member 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of BPIFA1 protein

NCBI chr 2:153,984,800...153,991,137
Ensembl chr 2:153,984,800...153,991,139

G

B-box and SPRY domain containing

increases expression

Dextran Sulfate results in increased expression of BSPRY mRNA

NCBI chr 4:62,398,248...62,415,537
Ensembl chr 4:62,398,290...62,415,535

G

bone marrow stromal cell antigen 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BST1 mRNA

NCBI chr 5:43,976,235...44,000,810
Ensembl chr 5:43,976,227...44,001,328

G

basic transcription factor 3-like 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of BTF3L4 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BTF3L4 protein]

NCBI chr 4:108,671,489...108,691,445
Ensembl chr 4:108,671,492...108,690,811

G

core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1 mRNA

NCBI chr 6:7,845,224...7,872,042
Ensembl chr 6:7,844,842...7,875,687

G

C1GALT1-specific chaperone 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1C1 mRNA

NCBI chr X:37,719,660...37,724,020
Ensembl chr X:37,719,662...37,723,964

G

complement component 1, q subcomponent, alpha polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QA mRNA

NCBI chr 4:136,623,227...136,626,155
Ensembl chr 4:136,623,228...136,626,114

G

complement component 1, q subcomponent, beta polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QB mRNA

NCBI chr 4:136,607,437...136,613,511
Ensembl chr 4:136,607,440...136,613,498

G

C1q and tumor necrosis factor related protein 6

decreases expression

Dextran Sulfate results in decreased expression of C1QTNF6 mRNA

NCBI chr15:78,407,546...78,416,370
Ensembl chr15:78,407,546...78,415,616

G

complement component 1, r subcomponent A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1RA mRNA

NCBI chr 6:124,489,580...124,500,399
Ensembl chr 6:124,489,364...124,500,402

G

complement component 1, s subcomponent 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1S1 mRNA

NCBI chr 6:124,507,303...124,519,340
Ensembl chr 6:124,507,304...124,519,318

G

complement component 1, s subcomponent 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1S2 mRNA

NCBI chr 6:124,601,584...124,613,044
Ensembl chr 6:124,601,584...124,613,044

G

complement component 3

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C3 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3 mRNA

PMID:29950665 PMID:35999755

NCBI chr17:57,510,967...57,535,136
Ensembl chr17:57,510,970...57,535,136

G

complement component 3a receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3AR1 mRNA

NCBI chr 6:122,824,099...122,833,116
Ensembl chr 6:122,824,097...122,833,120

G

complement C4B (Chido blood group)

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C4B mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of C4B protein]

PMID:29950665 PMID:32272095

NCBI chr17:34,947,249...34,962,876
Ensembl chr17:34,947,354...34,962,856

G

complement component 4 binding protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C4BP mRNA

NCBI chr 1:130,562,510...130,589,365
Ensembl chr 1:130,562,510...130,589,369

G

complement component 5a receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C5AR1 mRNA

NCBI chr 7:15,980,668...15,993,465
Ensembl chr 7:15,980,668...15,993,465

G

calcium binding protein 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAB39 mRNA

NCBI chr 1:85,707,796...85,779,298
Ensembl chr 1:85,721,162...85,779,297

G

calcium channel, voltage-dependent, alpha 1F subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CACNA1F mRNA

NCBI chr X:7,473,342...7,501,435
Ensembl chr X:7,473,322...7,501,435

G

calcium channel, voltage-dependent, L type, alpha 1S subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CACNA1S mRNA

NCBI chr 1:135,980,549...136,047,268
Ensembl chr 1:135,980,488...136,047,560

G

calcitonin/calcitonin-related polypeptide, alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CALCA mRNA

NCBI chr 7:114,225,223...114,236,145
Ensembl chr 7:114,230,713...114,235,592

G

calcitonin-related polypeptide, beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALCB mRNA

NCBI chr 7:114,315,790...114,322,603
Ensembl chr 7:114,317,878...114,322,600

G

calmodulin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALM1 mRNA

NCBI chr12:100,165,694...100,176,083
Ensembl chr12:100,165,694...100,176,073

G

calmodulin 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CALM2 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CALM2 protein

NCBI chr17:87,740,829...87,754,363
Ensembl chr17:87,740,840...87,754,363

G

calreticulin

decreases expression

Dextran Sulfate results in decreased expression of CALR protein

NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563

G

calcium/calmodulin-dependent protein kinase II gamma

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK2G mRNA

NCBI chr14:20,784,943...20,844,225
Ensembl chr14:20,784,943...20,844,156

G

calcium/calmodulin-dependent protein kinase IV

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK4 mRNA

NCBI chr18:33,067,995...33,328,820
Ensembl chr18:33,067,984...33,324,281

G

calcium/calmodulin-dependent protein kinase kinase 1, alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMKK1 mRNA

NCBI chr11:72,906,869...72,932,899
Ensembl chr11:72,909,834...72,932,899

G

cyclase associated actin cytoskeleton regulatory protein 1

decreases expression

Dextran Sulfate results in decreased expression of CAP1 protein

NCBI chr 4:122,752,841...122,779,869
Ensembl chr 4:122,752,840...122,779,849

G

calpain 13

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CAPN13 protein]

NCBI chr17:73,613,451...73,706,376
Ensembl chr17:73,613,459...73,707,861

G

capping actin protein of muscle Z-line subunit beta

decreases expression

Dextran Sulfate results in decreased expression of CAPZB protein

NCBI chr 4:138,920,210...139,019,131
Ensembl chr 4:138,920,210...139,019,129

G

carbonic anhydrase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAR2 mRNA

NCBI chr 3:14,951,329...14,965,830
Ensembl chr 3:14,951,333...14,965,830

G

carbonic anhydrase 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CA3 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CA3 protein]

NCBI chr 3:14,928,598...14,937,441
Ensembl chr 3:14,928,572...14,937,583

G

carbonic anhydrase 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CA4 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CA4 protein]

NCBI chr11:84,848,580...84,856,880
Ensembl chr11:84,848,612...84,856,870

G

caspase 1

multiple interactions
increases expression

3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein]; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 protein; [HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein; [Streptozocin co-treated with Dextran Sulfate] results in increased cleavage of CASP1 protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]]
Dextran Sulfate results in increased expression of CASP1 mRNA; Dextran Sulfate results in increased expression of CASP1 protein

PMID:27611972 PMID:30270565 PMID:32470352 PMID:34964214 PMID:37001609

NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290

G

caspase 3

increases cleavage
increases activity
multiple interactions

Dextran Sulfate results in increased cleavage of CASP3 protein
Dextran Sulfate results in increased activity of CASP3 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CASP3 mRNA; alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; biochanin A inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]

PMID:21989142 PMID:27920257 PMID:28421826 PMID:29950665 PMID:31676321 More...

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CASP8 protein
dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in decreased expression of CASP8 protein]

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

catalase

decreases activity
increases activity
multiple interactions

Dextran Sulfate results in decreased activity of CAT protein
Dextran Sulfate results in increased activity of CAT protein
[Streptozocin co-treated with Dextran Sulfate] results in decreased expression of CAT protein; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased activity of CAT protein]; gingerol inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; mangiferin inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]

PMID:27125760 PMID:28421826 PMID:30489199 PMID:31737179 PMID:34964214

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

caveolae associated 2

decreases expression

Dextran Sulfate results in decreased expression of CAVIN2 protein

NCBI chr 1:51,328,285...51,342,119
Ensembl chr 1:51,328,285...51,342,119

G

carbonyl reductase 1

decreases expression

Dextran Sulfate results in decreased expression of CBR1 protein

NCBI chr16:93,404,752...93,407,226
Ensembl chr16:93,402,741...93,407,393

G

carbonyl reductase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CBR3 mRNA

NCBI chr16:93,480,107...93,487,879
Ensembl chr16:93,480,103...93,487,878

G

coiled-coil domain containing 12

increases expression

Dextran Sulfate results in increased expression of CCDC12 mRNA

NCBI chr 9:110,483,376...110,540,661
Ensembl chr 9:110,485,571...110,540,674

G

coiled-coil domain containing 124

increases expression

Dextran Sulfate results in increased expression of CCDC124 mRNA

NCBI chr 8:71,320,870...71,326,134
Ensembl chr 8:71,320,871...71,326,579

G

coiled-coil domain containing 13

increases expression

Dextran Sulfate results in increased expression of CCDC13 mRNA

NCBI chr 9:121,626,690...121,668,581
Ensembl chr 9:121,626,693...121,668,527

G

coiled-coil domain containing 158

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CCDC158 protein]

NCBI chr 5:92,756,096...92,823,327
Ensembl chr 5:92,755,813...92,823,130

G

coiled-coil domain containing 88B

increases expression

Dextran Sulfate results in increased expression of CCDC88B mRNA

NCBI chr19:6,821,991...6,835,586
Ensembl chr19:6,821,991...6,835,579

G

coiled-coil domain containing 9

increases expression

Dextran Sulfate results in increased expression of CCDC9 mRNA

NCBI chr 7:16,005,938...16,020,713
Ensembl chr 7:16,007,967...16,020,720

G

coiled-coil domain containing 96

increases expression

Dextran Sulfate results in increased expression of CCDC96 mRNA

NCBI chr 5:36,641,932...36,645,515
Ensembl chr 5:36,641,932...36,645,516

G

coiled-coil alpha-helical rod protein 1

increases expression

Dextran Sulfate results in increased expression of CCHCR1 mRNA

NCBI chr17:35,827,914...35,841,912
Ensembl chr17:35,827,997...35,841,912

G

cholecystokinin B receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCKBR mRNA

NCBI chr 7:105,075,201...105,085,546
Ensembl chr 7:105,074,938...105,120,105

G

C-C motif chemokine ligand 11

increases secretion
increases expression
multiple interactions

Dextran Sulfate results in increased secretion of CCL11 protein
Dextran Sulfate results in increased expression of CCL11 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL11 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL11 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL11 protein]

PMID:21858153 PMID:29950665 PMID:32033881

NCBI chr11:81,948,658...81,953,781
Ensembl chr11:81,948,649...81,953,781

G

C-C motif chemokine ligand 2

increases secretion
increases expression
multiple interactions

Dextran Sulfate results in increased secretion of CCL2 protein
Dextran Sulfate results in increased expression of CCL2 mRNA
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of CCL2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL2 mRNA; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of CCL2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL2 protein]

PMID:19645018 PMID:20079348 PMID:21858153 PMID:24146755 PMID:29950665 More...

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 21 (serine)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL21A mRNA

NCBI chr 4:42,772,860...42,773,991
Ensembl chr 4:42,772,860...42,773,993

G

C-C motif chemokine ligand 24

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL24 mRNA

NCBI chr 5:135,598,789...135,601,977
Ensembl chr 5:135,598,791...135,601,903

G

C-C motif chemokine ligand 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL25 mRNA

NCBI chr 8:4,375,207...4,410,020
Ensembl chr 8:4,375,210...4,410,020

G

C-C motif chemokine ligand 27A

increases expression

Dextran Sulfate results in increased expression of CCL27A mRNA

NCBI chr 4:41,769,467...41,774,251
Ensembl chr 4:41,769,467...41,774,247

G

C-C motif chemokine ligand 28

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL28 mRNA

NCBI chr13:120,085,355...120,115,895
Ensembl chr13:120,085,355...120,115,895

G

C-C motif chemokine ligand 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CCL3 mRNA
ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]
Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 protein]

PMID:19645018 PMID:30811821 PMID:33130971

NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181

G

C-C motif chemokine ligand 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL4 mRNA

NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509

G

C-C motif chemokine ligand 6

decreases expression
increases expression

Dextran Sulfate results in decreased expression of CCL6 mRNA
Dextran Sulfate results in increased expression of CCL6 mRNA

PMID:19645018 PMID:35093514

NCBI chr11:83,478,712...83,483,913
Ensembl chr11:83,478,708...83,483,913

G

C-C motif chemokine ligand 7

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CCL7 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL7 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL7 mRNA]

PMID:19645018 PMID:29950665 PMID:32033881

NCBI chr11:81,936,538...81,938,351
Ensembl chr11:81,936,538...81,938,351

G

C-C motif chemokine ligand 8

increases expression

Dextran Sulfate results in increased expression of CCL8 mRNA

PMID:19645018 PMID:23894361

NCBI chr11:82,006,011...82,007,625
Ensembl chr11:82,006,011...82,007,625

G

C-C motif chemokine ligand 9

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL9 mRNA
Dextran Sulfate results in increased expression of CCL9 mRNA

PMID:29950665 PMID:35093514

NCBI chr11:83,463,743...83,469,462
Ensembl chr11:83,463,745...83,469,462

G

cyclin D1

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein]

PMID:31715269 PMID:35439472

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

C-C motif chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR2 mRNA

NCBI chr 9:123,901,954...123,913,594
Ensembl chr 9:123,901,987...123,913,594

G

C-C motif chemokine receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR4 mRNA

NCBI chr 9:114,319,384...114,334,544
Ensembl chr 9:114,319,384...114,333,984

G

C-C motif chemokine receptor 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR5 mRNA

NCBI chr 9:123,921,557...123,934,153
Ensembl chr 9:123,921,580...123,947,736

G

C-C motif chemokine receptor 7

multiple interactions

Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 protein]

NCBI chr11:99,035,025...99,045,903
Ensembl chr11:99,035,022...99,045,903

G

C-C motif chemokine receptor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR8 mRNA

NCBI chr 9:119,921,199...119,923,972
Ensembl chr 9:119,921,180...119,923,972

G

C-C motif chemokine receptor-like 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCRL2 mRNA

NCBI chr 9:110,883,902...110,886,586
Ensembl chr 9:110,883,554...110,886,587

G

centriole, cilia and spindle associated protein

increases expression

Dextran Sulfate results in increased expression of CCSAP mRNA

NCBI chr 8:124,566,712...124,586,948
Ensembl chr 8:124,567,570...124,586,948

G

CD14 antigen

multiple interactions
affects response to substance

[Dextran Sulfate affects the susceptibility to CD14 protein] which affects the expression of IFNG mRNA; CD14 protein inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]

NCBI chr18:36,858,117...36,859,868
Ensembl chr18:36,858,120...36,859,851

G

CD163 antigen

increases expression

Dextran Sulfate results in increased expression of CD163 mRNA

NCBI chr 6:124,281,596...124,307,488
Ensembl chr 6:124,281,615...124,307,486

G

CD177 antigen

increases expression

Dextran Sulfate results in increased expression of CD177 mRNA

NCBI chr 7:24,443,408...24,459,759
Ensembl chr 7:24,443,408...24,459,736

G

CD180 antigen

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CD180 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD180 mRNA

PMID:23894361 PMID:29950665

NCBI chr13:102,830,055...102,843,139
Ensembl chr13:102,830,066...102,876,137

G

CD19 antigen

increases expression

Dextran Sulfate results in increased expression of CD19 mRNA

NCBI chr 7:126,007,620...126,016,401
Ensembl chr 7:126,007,622...126,014,061

G

CD200 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD200 mRNA

NCBI chr16:45,202,474...45,229,419
Ensembl chr16:45,202,498...45,229,416

G

CD209f antigen

decreases expression

Dextran Sulfate results in decreased expression of CD209F mRNA

NCBI chr 8:4,152,784...4,155,838
Ensembl chr 8:4,152,787...4,155,835

G

CD247 antigen

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD247 mRNA

NCBI chr 1:165,607,514...165,698,722
Ensembl chr 1:165,616,250...165,704,846

G

CD274 antigen

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD274 mRNA

NCBI chr19:29,339,428...29,365,495
Ensembl chr19:29,344,855...29,365,495

G

CD28 antigen

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD28 mRNA

NCBI chr 1:60,785,547...60,812,521
Ensembl chr 1:60,755,959...60,812,518

G

CD34 antigen

decreases expression

Dextran Sulfate results in decreased expression of CD34 mRNA

NCBI chr 1:194,621,239...194,643,587
Ensembl chr 1:194,621,127...194,643,587

G

CD4 antigen

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD4 mRNA

NCBI chr 6:124,841,656...124,865,210
Ensembl chr 6:124,841,655...124,865,184

G

CD44 antigen

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of CD44 mRNA

NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010

G

CD52 antigen

increases expression

Dextran Sulfate results in increased expression of CD52 mRNA

NCBI chr 4:133,820,849...133,822,384
Ensembl chr 4:133,809,759...133,822,393

G

CD53 antigen

increases expression

Dextran Sulfate results in increased expression of CD53 mRNA

NCBI chr 3:106,666,177...106,697,465
Ensembl chr 3:106,667,237...106,697,465

G

CD55 molecule, decay accelerating factor for complement

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD55 mRNA

NCBI chr 1:130,357,526...130,390,513
Ensembl chr 1:130,366,764...130,390,481

G

CD55 molecule, decay accelerating factor for complement B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD55B mRNA

NCBI chr 1:130,316,263...130,350,831
Ensembl chr 1:130,316,274...130,350,746

G

CD68 antigen

increases expression

dextran sulfate increases expression of CD68 protein in colonic lamina propria of mice

RGD

NCBI chr11:69,555,039...69,556,996
Ensembl chr11:69,555,039...69,556,979

G

CD72 antigen

increases expression

Dextran Sulfate results in increased expression of CD72 mRNA

NCBI chr 4:43,447,724...43,454,708
Ensembl chr 4:43,446,462...43,454,628

G

CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)

increases expression
decreases expression

Dextran Sulfate results in increased expression of CD74 mRNA
Dextran Sulfate results in decreased expression of CD74 mRNA

PMID:23894361 PMID:35093514

NCBI chr18:60,936,921...60,945,724
Ensembl chr18:60,936,920...60,945,724

G

CD79A antigen (immunoglobulin-associated alpha)

increases expression

Dextran Sulfate results in increased expression of CD79A mRNA

NCBI chr 7:24,596,922...24,601,283
Ensembl chr 7:24,596,806...24,601,622

G

CD79B antigen

increases expression

Dextran Sulfate results in increased expression of CD79B mRNA

NCBI chr11:106,202,167...106,205,388
Ensembl chr11:106,202,167...106,205,588

G

CD81 antigen

decreases expression

Dextran Sulfate results in decreased expression of CD81 mRNA

NCBI chr 7:142,606,487...142,621,667
Ensembl chr 7:142,606,476...142,621,671

G

CD86 antigen

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD86 mRNA; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 protein]
Dextran Sulfate results in increased expression of CD86 mRNA; Dextran Sulfate results in increased expression of CD86 protein

PMID:29950665 PMID:38164749

NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443

G

cytidine deaminase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDA mRNA

NCBI chr 4:138,065,839...138,095,623
Ensembl chr 4:138,065,735...138,095,303

G

cadherin 1

multiple interactions
decreases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of CDH1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH1 mRNA
Dextran Sulfate results in decreased expression of CDH1 mRNA; Dextran Sulfate results in decreased expression of CDH1 protein

PMID:29950665 PMID:34273909 PMID:36543318 PMID:37385329

NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878

G

cadherin 2

multiple interactions
increases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CDH2 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH2 protein

PMID:34273909 PMID:36543318

NCBI chr18:16,721,934...16,942,303
Ensembl chr18:16,721,934...16,942,303

G

cadherin 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH5 mRNA

NCBI chr 8:104,828,247...104,871,136
Ensembl chr 8:104,828,257...104,871,143

G

cadherin-related family member 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CDHR2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CDHR2 protein]

NCBI chr13:54,849,276...54,884,475
Ensembl chr13:54,849,274...54,884,475

G

cyclin dependent kinase 11B

increases expression

Dextran Sulfate results in increased expression of CDK11B mRNA

NCBI chr 4:155,709,303...155,734,392
Ensembl chr 4:155,709,311...155,734,395

G

cyclin dependent kinase inhibitor 1C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDKN1C mRNA

NCBI chr 7:143,012,076...143,014,735
Ensembl chr 7:143,012,076...143,014,787

G

caudal type homeobox 2

multiple interactions
decreases expression
increases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CDX2 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in decreased expression of CDX2 protein]

PMID:29680209 PMID:38663798

NCBI chr 5:147,237,710...147,244,059
Ensembl chr 5:147,237,615...147,244,080

G

CEA cell adhesion molecule 12

increases expression

Dextran Sulfate results in increased expression of CEACAM12 mRNA

NCBI chr 7:17,799,854...17,811,911
Ensembl chr 7:17,799,854...17,811,911

G

CCAAT/enhancer binding protein delta

increases expression

Dextran Sulfate results in increased expression of CEBPD mRNA

NCBI chr16:15,705,150...15,707,409
Ensembl chr16:15,705,150...15,708,895

G

carboxyl ester lipase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CEL mRNA

NCBI chr 2:28,445,831...28,453,415
Ensembl chr 2:28,445,807...28,453,415

G

centrosomal protein 131

increases expression

Dextran Sulfate results in increased expression of CEP131 mRNA

NCBI chr11:119,955,247...119,977,684
Ensembl chr11:119,955,256...119,977,653

G

carboxylesterase 1D

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CES1D protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES1D mRNA
Dextran Sulfate results in decreased expression of CES1D mRNA

PMID:29950665 PMID:35093514 PMID:35999755

NCBI chr 8:93,892,700...93,924,432
Ensembl chr 8:93,892,696...93,924,466

G

carboxylesterase 1E

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES1E mRNA

NCBI chr 8:93,927,846...93,956,233
Ensembl chr 8:93,927,846...93,956,247

G

carboxylesterase 2A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2A mRNA

NCBI chr 8:105,460,635...105,468,266
Ensembl chr 8:105,460,635...105,468,266

G

carboxylesterase 2C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2C mRNA

NCBI chr 8:105,573,700...105,581,115
Ensembl chr 8:105,573,700...105,581,115

G

carboxylesterase 2E

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2E mRNA

NCBI chr 8:105,652,892...105,661,304
Ensembl chr 8:105,652,892...105,661,304

G

carboxylesterase 2G

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CES2G mRNA

NCBI chr 8:105,688,350...105,696,169
Ensembl chr 8:105,688,350...105,696,169

G

cilia and flagella associated protein 45

increases expression

Dextran Sulfate results in increased expression of CFAP45 mRNA

NCBI chr 1:172,348,697...172,373,437
Ensembl chr 1:172,348,368...172,373,437

G

complement factor B

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFB protein

NCBI chr17:35,075,350...35,081,492
Ensembl chr17:35,075,350...35,081,494

G

complement factor D

increases expression

Dextran Sulfate results in increased expression of CFD protein

NCBI chr10:79,726,687...79,728,489
Ensembl chr10:79,726,687...79,728,489

G

complement component factor h

multiple interactions
increases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFH protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CFH mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CFH protein]
Dextran Sulfate results in increased expression of CFH mRNA; Dextran Sulfate results in increased expression of CFH protein

PMID:29950665 PMID:32272095 PMID:35093514 PMID:35999755

NCBI chr 1:140,013,593...140,111,149
Ensembl chr 1:140,012,446...140,111,502

G

cofilin 1, non-muscle

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CFL1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CFL1 protein

NCBI chr19:5,540,483...5,544,059
Ensembl chr19:5,540,483...5,545,229

G

CASP8 and FADD-like apoptosis regulator

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]

NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043

G

cystic fibrosis transmembrane conductance regulator

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFTR mRNA

NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767

G

cell growth regulator with EF hand domain 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CGREF1 protein

NCBI chr 5:31,090,487...31,102,771
Ensembl chr 5:31,090,487...31,102,935

G

chromatin assembly factor 1, subunit A

increases expression

Dextran Sulfate results in increased expression of CHAF1A mRNA

NCBI chr17:56,347,404...56,375,027
Ensembl chr17:56,347,439...56,379,289

G

calcium homeostasis endoplasmic reticulum protein

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CHERP protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHERP protein]

NCBI chr 8:73,214,327...73,229,077
Ensembl chr 8:73,214,333...73,229,070

G

chitinase-like 3

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHIL3 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHIL3 mRNA]

NCBI chr 3:106,054,870...106,074,852
Ensembl chr 3:106,054,870...106,074,880

G

charged multivesicular body protein 2A

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CHMP2A protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHMP2A protein]

NCBI chr 7:12,765,933...12,768,704
Ensembl chr 7:12,765,937...12,768,734

G

charged multivesicular body protein 4B

increases expression

Dextran Sulfate results in increased expression of CHMP4B mRNA

NCBI chr 2:154,498,949...154,536,703
Ensembl chr 2:154,493,625...154,536,705

G

chimerin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHN2 mRNA

NCBI chr 6:54,016,917...54,278,797
Ensembl chr 6:54,016,539...54,278,795

G

chordin-like 2

increases expression

Dextran Sulfate results in increased expression of CHRDL2 mRNA

NCBI chr 7:99,655,611...99,683,935
Ensembl chr 7:99,655,379...99,683,935

G

cholinergic receptor, muscarinic 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRM4 mRNA

NCBI chr 2:91,752,531...91,760,180
Ensembl chr 2:91,757,594...91,759,033

G

cholinergic receptor nicotinic alpha 2 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA2 mRNA

NCBI chr14:66,370,685...66,390,397
Ensembl chr14:66,372,488...66,390,397

G

cholinergic receptor, nicotinic, alpha polypeptide 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA7 mRNA

NCBI chr 7:62,748,440...62,862,274
Ensembl chr 7:62,748,440...62,862,317

G

cholinergic receptor, nicotinic, beta polypeptide 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRNB3 mRNA

NCBI chr 8:27,858,688...27,889,758
Ensembl chr 8:27,858,739...27,889,758

G

cholinergic receptor, nicotinic, epsilon polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNE mRNA

NCBI chr11:70,505,709...70,510,074
Ensembl chr11:70,505,709...70,510,042

G

carbohydrate sulfotransferase 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHST11 mRNA

NCBI chr10:82,820,274...83,031,738
Ensembl chr10:82,821,332...83,031,734

G

conserved helix-loop-helix ubiquitous kinase

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CHUK protein modified form
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of CHUK protein modified form]

NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919

G

creatine kinase, brain

decreases expression

Dextran Sulfate results in decreased expression of CKB protein

NCBI chr12:111,635,789...111,638,772
Ensembl chr12:111,635,795...111,638,772

G

creatine kinase, muscle

decreases expression

Dextran Sulfate results in decreased expression of CKM protein

NCBI chr 7:19,145,019...19,155,508
Ensembl chr 7:19,138,701...19,156,766

G

chloride channel accessory 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCA1 mRNA

NCBI chr 3:144,710,298...144,738,537
Ensembl chr 3:144,709,578...144,738,537

G

chloride channel accessory 4A

increases expression

Dextran Sulfate results in increased expression of CLCA4 mRNA

NCBI chr 3:144,658,247...144,680,806
Ensembl chr 3:144,658,241...144,680,806

G

chloride channel, voltage-sensitive 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN2 mRNA

NCBI chr16:20,521,185...20,536,496
Ensembl chr16:20,521,714...20,536,496

G

chloride channel, voltage-sensitive 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN3 mRNA

NCBI chr 8:61,363,423...61,436,351
Ensembl chr 8:61,363,423...61,436,334

G

claudin 1

decreases expression
increases expression
multiple interactions

Dextran Sulfate results in decreased expression of CLDN1 protein
Dextran Sulfate results in increased expression of CLDN1 protein
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN1 protein]; [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; [SB 203580 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]

PMID:27920472 PMID:36543318 PMID:37001609 PMID:38648921

NCBI chr16:26,175,395...26,190,589
Ensembl chr16:26,175,392...26,190,591

G

claudin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CLDN11 mRNA

NCBI chr 3:31,204,069...31,218,475
Ensembl chr 3:31,204,069...31,218,473

G

claudin 2

multiple interactions
increases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of CLDN2 mRNA
Dextran Sulfate results in increased expression of CLDN2 mRNA; Dextran Sulfate results in increased expression of CLDN2 protein

PMID:26271895 PMID:29680209 PMID:36543318

NCBI chr X:138,701,552...138,712,135
Ensembl chr X:138,701,577...138,712,135

G

C-type lectin domain family 10, member A

increases expression

Dextran Sulfate results in increased expression of CLEC10A mRNA

NCBI chr11:70,057,449...70,061,662
Ensembl chr11:70,047,023...70,061,660

G

chloride intracellular channel 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CLIC1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CLIC1 protein

NCBI chr17:35,269,219...35,277,695
Ensembl chr17:35,268,942...35,277,725

G

chymase 1, mast cell

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CMA1 mRNA

NCBI chr14:56,178,908...56,182,132
Ensembl chr14:56,178,908...56,182,132

G

cytidine monophospho-N-acetylneuraminic acid synthetase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CMAS mRNA

NCBI chr 6:142,702,468...142,721,440
Ensembl chr 6:142,702,412...142,721,440

G

cytidine/uridine monophosphate kinase 1

decreases expression

Dextran Sulfate results in decreased expression of CMPK1 protein

NCBI chr 4:114,817,810...114,844,425
Ensembl chr 4:114,816,533...114,844,438

G

cyclic nucleotide gated channel alpha 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNGA4 mRNA

NCBI chr 7:105,049,247...105,057,981
Ensembl chr 7:105,053,775...105,057,949

G

calponin 2

decreases expression

Dextran Sulfate results in decreased expression of CNN2 protein

NCBI chr10:79,824,434...79,831,234
Ensembl chr10:79,824,418...79,831,896

G

cannabinoid receptor 1

decreases response to substance
increases expression
multiple interactions

CNR1 results in decreased susceptibility to Dextran Sulfate
Dextran Sulfate results in increased expression of CNR1 protein
SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]; Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]

PMID:15085199 PMID:27920472 PMID:30611738

NCBI chr 4:33,923,171...33,948,831
Ensembl chr 4:33,924,593...33,948,831

G

cannabinoid receptor 2

multiple interactions
increases response to substance
affects response to substance
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CNR2 mRNA; CNR2 gene mutant form promotes the reaction [Dextran Sulfate results in increased secretion of MPO protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]; CNR2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR2 protein]
CNR2 gene mutant form results in increased susceptibility to Dextran Sulfate
CNR2 protein affects the susceptibility to Dextran Sulfate

PMID:27611972 PMID:27920472 PMID:29950665 PMID:30102254 PMID:32942172

NCBI chr 4:135,622,500...135,647,530
Ensembl chr 4:135,622,705...135,647,518

G

ciliary neurotrophic factor receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTFR mRNA

NCBI chr 4:41,657,498...41,697,091
Ensembl chr 4:41,657,498...41,697,089

G

contactin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTN1 mRNA

NCBI chr15:91,949,034...92,239,834
Ensembl chr15:91,949,046...92,239,848

G

component of oligomeric golgi complex 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COG1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COG1 protein]

NCBI chr11:113,540,004...113,560,157
Ensembl chr11:113,539,995...113,557,880

G

collagen, type XI, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL11A1 mRNA

NCBI chr 3:113,823,933...114,014,405
Ensembl chr 3:113,824,189...114,014,367

G

collagen, type XIV, alpha 1

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL14A1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of COL14A1 protein]

PMID:29950665 PMID:32272095

NCBI chr15:55,171,040...55,384,199
Ensembl chr15:55,171,146...55,384,199

G

collagen, type XVI, alpha 1

increases expression

Dextran Sulfate results in increased expression of COL16A1 mRNA

NCBI chr 4:129,941,638...129,993,070
Ensembl chr 4:129,941,633...129,993,076

G

collagen, type XVIII, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL18A1 mRNA

NCBI chr10:76,888,013...77,002,351
Ensembl chr10:76,888,012...77,002,382

G

collagen, type I, alpha 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL1A1 mRNA
Dextran Sulfate results in decreased expression of COL1A1 mRNA

PMID:29950665 PMID:35093514

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

collagen, type I, alpha 2

decreases expression

Dextran Sulfate results in decreased expression of COL1A2 mRNA

NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544

G

collagen, type XXII, alpha 1

increases expression

Dextran Sulfate results in increased expression of COL22A1 mRNA

NCBI chr15:71,667,644...71,906,087
Ensembl chr15:71,667,644...71,906,076

G

collagen, type XXIII, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL23A1 mRNA

NCBI chr11:51,180,508...51,474,752
Ensembl chr11:51,180,747...51,474,745

G

collagen, type XXVIII, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL28A1 mRNA

NCBI chr 6:7,997,100...8,193,709
Ensembl chr 6:7,997,808...8,192,617

G

collagen, type III, alpha 1

decreases expression

Dextran Sulfate results in decreased expression of COL3A1 mRNA

NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866

G

collagen, type IV, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A1 mRNA

NCBI chr 8:11,248,423...11,362,889
Ensembl chr 8:11,248,423...11,362,826

G

collagen, type IV, alpha 2

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A2 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL4A2 protein]

PMID:29950665 PMID:32272095

NCBI chr 8:11,362,878...11,499,287
Ensembl chr 8:11,362,805...11,499,287

G

collagen, type V, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A1 mRNA

NCBI chr 2:27,776,393...27,929,522
Ensembl chr 2:27,776,437...27,929,526

G

collagen, type V, alpha 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A2 mRNA

NCBI chr 1:45,413,491...45,542,442
Ensembl chr 1:45,413,481...45,542,442

G

collagen, type VI, alpha 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COL6A1 mRNA; Dextran Sulfate results in decreased expression of COL6A1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A1 protein]

PMID:32272095 PMID:35093514

NCBI chr10:76,544,626...76,561,869
Ensembl chr10:76,544,626...76,562,002

G

collagen, type VI, alpha 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COL6A2 mRNA; Dextran Sulfate results in decreased expression of COL6A2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A2 protein]

PMID:32272095 PMID:35093514

NCBI chr10:76,431,590...76,459,464
Ensembl chr10:76,431,596...76,459,464

G

collagen, type VI, alpha 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COL6A4 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A4 protein]

NCBI chr 9:105,867,284...105,975,729
Ensembl chr 9:105,866,653...105,973,982

G

collagen, type VIII, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL8A1 mRNA

NCBI chr16:57,444,619...57,575,100
Ensembl chr16:57,444,621...57,575,100

G

coronin, actin binding protein 1A

decreases expression

Dextran Sulfate results in decreased expression of CORO1A protein

NCBI chr 7:126,298,946...126,303,925
Ensembl chr 7:126,298,945...126,306,959

G

coronin, actin binding protein 1C

decreases expression

Dextran Sulfate results in decreased expression of CORO1C protein

NCBI chr 5:113,980,500...114,046,767
Ensembl chr 5:113,980,497...114,046,819

G

coactosin like F-actin binding protein 1

decreases expression

Dextran Sulfate results in decreased expression of COTL1 protein

NCBI chr 8:120,535,953...120,567,318
Ensembl chr 8:120,535,961...120,567,283

G

cytochrome c oxidase subunit 5B

increases expression

Dextran Sulfate results in increased expression of COX5B mRNA

NCBI chr 1:36,730,568...36,732,469
Ensembl chr 1:36,730,530...36,732,762

G

ceruloplasmin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CP mRNA

NCBI chr 3:20,011,097...20,063,914
Ensembl chr 3:20,011,218...20,063,309

G

carboxypeptidase A1, pancreatic

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CPA1 mRNA

NCBI chr 6:30,639,217...30,645,360
Ensembl chr 6:30,639,217...30,645,362

G

carboxypeptidase B2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CPB2 mRNA

NCBI chr14:75,479,727...75,520,995
Ensembl chr14:75,479,727...75,520,995

G

complement receptor 2

increases expression

Dextran Sulfate results in increased expression of CR2 mRNA

NCBI chr 1:194,819,120...194,859,096
Ensembl chr 1:194,819,119...194,859,024

G

capping protein inhibiting regulator of actin

increases expression

Dextran Sulfate results in increased expression of CRACD mRNA

NCBI chr 5:76,803,225...77,021,393
Ensembl chr 5:76,804,359...77,021,392

G

corticotropin releasing hormone receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CRHR1 mRNA

NCBI chr11:104,021,289...104,066,349
Ensembl chr11:104,023,681...104,066,349

G

corticotropin releasing hormone receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRHR2 mRNA

NCBI chr 6:55,067,033...55,110,001
Ensembl chr 6:55,067,034...55,110,001

G

cysteine-rich secretory protein 4

decreases expression

Dextran Sulfate results in decreased expression of CRISP1 protein

NCBI chr 1:18,185,113...18,216,126
Ensembl chr 1:18,185,415...18,216,126

G

cartilage associated protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRTAP mRNA

NCBI chr 9:114,204,204...114,219,743
Ensembl chr 9:114,204,202...114,219,743

G

colony stimulating factor 1 (macrophage)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF1 mRNA

NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785

G

colony stimulating factor 2 (granulocyte-macrophage)

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CSF2 mRNA; Dextran Sulfate results in increased expression of CSF2 protein
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2 mRNA; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 mRNA]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of CSF2 protein]

PMID:15652231 PMID:29950665 PMID:31442584

NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493

G

colony stimulating factor 2 receptor, beta 2, low-affinity (granulocyte-macrophage)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2RB2 mRNA

NCBI chr15:78,166,707...78,189,921
Ensembl chr15:78,166,707...78,189,921

G

colony stimulating factor 3 (granulocyte)

multiple interactions
increases expression

Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CSF3 mRNA]

NCBI chr11:98,591,287...98,594,457
Ensembl chr11:98,592,089...98,594,455

G

colony stimulating factor 3 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CSF3R mRNA

NCBI chr 4:125,917,241...125,938,233
Ensembl chr 4:125,918,343...125,938,233

G

catenin beta 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CTNNB1 protein
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of CTNNB1 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased mutagenesis of CTNNB1 gene; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein]; CTNNB1 gene mutant form results in increased susceptibility to [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate]

PMID:15459021 PMID:16049979 PMID:27664423 PMID:31715269

NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573

G

cytidine 5'-triphosphate synthase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CTPS1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTPS1 protein]

NCBI chr 4:120,397,065...120,427,473
Ensembl chr 4:120,397,065...120,427,473

G

cathepsin C

decreases expression

Dextran Sulfate results in decreased expression of CTSC mRNA

NCBI chr 7:87,927,233...87,960,083
Ensembl chr 7:87,927,293...87,960,096

G

cathepsin D

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CTSD protein]

NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775

G

cathepsin K

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSK mRNA

NCBI chr 3:95,406,521...95,416,698
Ensembl chr 3:95,406,567...95,416,673

G

cathepsin L

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CTSL protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSL mRNA

PMID:29950665 PMID:35999755

NCBI chr13:64,509,704...64,518,586
Ensembl chr13:64,507,151...64,518,704

G

cathepsin S

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CTSS protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTSS protein]

NCBI chr 3:95,434,097...95,463,716
Ensembl chr 3:95,434,097...95,463,714

G

cubilin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CUBN mRNA

NCBI chr 2:13,281,149...13,496,687
Ensembl chr 2:13,281,149...13,496,624

G

C-X3-C motif chemokine receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CX3CR1 mRNA

NCBI chr 9:119,877,749...119,897,362
Ensembl chr 9:119,877,749...119,898,945

G

coxsackie virus and adenovirus receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXADR mRNA

NCBI chr16:78,098,114...78,156,673
Ensembl chr16:78,098,377...78,156,662

G

C-X-C motif chemokine ligand 10

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA]

NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748

G

C-X-C motif chemokine ligand 12

decreases expression

Dextran Sulfate results in decreased expression of CXCL12 mRNA

NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328

G

C-X-C motif chemokine ligand 13

increases expression

Dextran Sulfate results in increased expression of CXCL13 mRNA

PMID:23894361 PMID:35093514

NCBI chr 5:96,104,785...96,108,927
Ensembl chr 5:96,104,810...96,108,927

G

C-X-C motif chemokine ligand 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL14 mRNA

NCBI chr13:56,436,456...56,444,624
Ensembl chr13:56,436,456...56,444,364

G

C-X-C motif chemokine ligand 15

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CXCL15 protein; Dextran Sulfate results in increased expression of CXCL8 protein
Dextran Sulfate results in increased expression of CXCL8 mRNA
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CXCL8 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of CXCL8 protein]

PMID:20637373 PMID:32272095 PMID:38423481

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

C-X-C motif chemokine ligand 2

multiple interactions
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]
Dextran Sulfate results in increased expression of CXCL2 mRNA; Dextran Sulfate results in increased expression of CXCL2 protein

PMID:21724996 PMID:32033881 PMID:34998820 PMID:36519841

NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797

G

C-X-C motif chemokine ligand 3

multiple interactions
increases secretion
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXCL1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL1 mRNA; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CXCL1 protein]
Dextran Sulfate results in increased expression of CXCL1 mRNA; Dextran Sulfate results in increased expression of CXCL1 protein

PMID:19645018 PMID:20079348 PMID:21724996 PMID:21858153 PMID:29950665 More...

NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459

G

C-X-C motif chemokine ligand 5

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CXCL5 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL5 mRNA

PMID:19645018 PMID:29950665

NCBI chr 5:90,907,157...90,909,484
Ensembl chr 5:90,907,219...90,909,483

G

C-X-C motif chemokine ligand 9

increases expression

Dextran Sulfate results in increased expression of CXCL9 mRNA

NCBI chr 5:92,469,190...92,475,938
Ensembl chr 5:92,469,206...92,475,938

G

C-X-C motif chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCR2 mRNA

NCBI chr 1:74,193,153...74,200,405
Ensembl chr 1:74,193,150...74,200,405

G

cytochrome b-245, alpha polypeptide

increases expression

Dextran Sulfate results in increased expression of CYBA protein

NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669

G

cytochrome b-245, beta polypeptide

increases expression

Dextran Sulfate results in increased expression of CYBB mRNA; Dextran Sulfate results in increased expression of CYBB protein

PMID:20637373 PMID:23894361

NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010

G

cytoplasmic FMR1 interacting protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP1 mRNA

NCBI chr 7:55,491,556...55,582,381
Ensembl chr 7:55,491,493...55,582,350

G

cytoplasmic FMR1 interacting protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP2 mRNA

NCBI chr11:46,084,676...46,203,686
Ensembl chr11:46,084,677...46,203,686

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP11A1 mRNA

NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP17A1 mRNA

NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 protein]; Dextran Sulfate inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
Dextran Sulfate results in decreased expression of CYP1A1 mRNA; Dextran Sulfate results in decreased expression of CYP1A1 protein

PMID:29680209 PMID:34998820

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of CYP1A2 protein
[Dextran Sulfate results in decreased activity of CYP1A2 protein] which results in decreased chemical synthesis of Acetaminophen

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 21, subfamily a, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP21A1 mRNA

NCBI chr17:35,020,322...35,023,400
Ensembl chr17:35,020,322...35,023,535

G

cytochrome P450, family 24, subfamily a, polypeptide 1

increases expression

Dextran Sulfate results in increased expression of CYP24A1 protein

NCBI chr 2:170,324,877...170,339,065
Ensembl chr 2:170,324,628...170,339,065

G

cytochrome P450, family 26, subfamily b, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP26B1 mRNA

NCBI chr 6:84,548,396...84,570,890
Ensembl chr 6:84,548,396...84,570,890

G

cytochrome P450, family 27, subfamily b, polypeptide 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP27B1 mRNA
Dextran Sulfate results in decreased expression of CYP27B1 protein

PMID:29950665 PMID:38588969

NCBI chr10:126,884,115...126,891,897
Ensembl chr10:126,884,119...126,888,875

G

cytochrome P450, family 2, subfamily b, polypeptide 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2B10 mRNA

NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049

G

cytochrome P450, family 2, subfamily b, polypeptide 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2B13 mRNA

NCBI chr 7:25,760,813...25,795,622
Ensembl chr 7:25,760,922...25,795,622

G

cytochrome P450, family 2, subfamily c, polypeptide 23

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2C23 mRNA

NCBI chr19:43,993,461...44,017,695
Ensembl chr19:43,993,461...44,017,647

G

cytochrome P450, family 2, subfamily c, polypeptide 29

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C29 mRNA

NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157

G

cytochrome P450, family 2, subfamily c, polypeptide 38

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C38 mRNA

NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519

G

cytochrome P450, family 2, subfamily c, polypeptide 40

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C40 mRNA

NCBI chr19:39,755,517...39,801,258
Ensembl chr19:39,755,515...39,801,258

G

cytochrome P450, family 2, subfamily c, polypeptide 50

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C50 mRNA

NCBI chr19:40,078,123...40,102,399
Ensembl chr19:40,078,132...40,102,394

G

cytochrome P450, family 2, subfamily c, polypeptide 55

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C55 mRNA

NCBI chr19:38,995,384...39,031,134
Ensembl chr19:38,995,463...39,031,137

G

cytochrome P450, family 2, subfamily c, polypeptide 65

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C65 mRNA

NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388

G

cytochrome P450, family 2, subfamily c, polypeptide 66

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C66 mRNA

NCBI chr19:39,102,342...39,175,200
Ensembl chr19:39,102,342...39,175,516

G

cytochrome P450, family 2, subfamily c, polypeptide 67

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C67 mRNA

NCBI chr19:39,597,288...39,637,497
Ensembl chr19:39,597,286...39,637,495

G

cytochrome P450, family 2, subfamily c, polypeptide 68

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C68 mRNA

NCBI chr19:39,677,280...39,729,545
Ensembl chr19:39,677,278...39,729,498

G

cytochrome P450, family 2, subfamily c, polypeptide 69

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C69 mRNA

NCBI chr19:39,831,104...39,875,213
Ensembl chr19:39,831,258...39,875,243

G

cytochrome P450, family 2, subfamily d, polypeptide 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D10 mRNA

NCBI chr15:82,287,046...82,291,449
Ensembl chr15:82,287,047...82,291,396

G

cytochrome P450, family 2, subfamily d, polypeptide 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D11 mRNA

NCBI chr15:82,273,355...82,278,223
Ensembl chr15:82,273,355...82,278,223

G

cytochrome P450, family 2, subfamily d, polypeptide 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D12 mRNA

NCBI chr15:82,439,244...82,443,614
Ensembl chr15:82,439,273...82,444,604

G

cytochrome P450, family 2, subfamily d, polypeptide 26

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D26 mRNA

NCBI chr15:82,674,308...82,678,653
Ensembl chr15:82,674,302...82,678,495

G

cytochrome P450, family 2, subfamily d, polypeptide 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D9 mRNA

NCBI chr15:82,336,578...82,341,028
Ensembl chr15:82,317,638...82,341,046

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of CYP2E1 protein
[Dextran Sulfate results in decreased activity of CYP2E1 protein] which results in decreased chemical synthesis of 6-hydroxychlorzoxazone

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

cytochrome P450, family 2, subfamily j, polypeptide 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J13 mRNA

NCBI chr 4:95,930,897...95,965,803
Ensembl chr 4:95,915,771...95,965,783

G

cytochrome P450, family 2, subfamily j, polypeptide 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J6 mRNA

NCBI chr 4:96,404,375...96,449,835
Ensembl chr 4:96,404,375...96,441,898

G

cytochrome P450, family 2, subfamily j, polypeptide 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J8 mRNA

NCBI chr 4:96,332,187...96,395,634
Ensembl chr 4:96,332,833...96,395,623

G

cytochrome P450, family 2, subfamily j, polypeptide 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J9 mRNA

NCBI chr 4:96,456,661...96,480,748
Ensembl chr 4:96,456,666...96,479,815

G

cytochrome P450, family 2, subfamily r, polypeptide 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2R1 mRNA; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of CYP2R1 protein]

PMID:29950665 PMID:38588969

NCBI chr 7:114,149,358...114,162,283
Ensembl chr 7:114,148,917...114,162,207

G

cytochrome P450, family 2, subfamily s, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2S1 mRNA

NCBI chr 7:25,501,894...25,515,950
Ensembl chr 7:25,501,900...25,516,338

G

cytochrome P450, family 3, subfamily a, polypeptide 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A11 mRNA

NCBI chr 5:145,791,417...145,816,664
Ensembl chr 5:145,791,236...145,816,774

G

cytochrome P450, family 3, subfamily a, polypeptide 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA

NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881

G

cytochrome P450, family 3, subfamily a, polypeptide 16

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A16 mRNA

NCBI chr 5:145,373,119...145,406,550
Ensembl chr 5:145,373,119...145,406,533

G

cytochrome P450, family 4, subfamily a, polypeptide 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4A10 mRNA

NCBI chr 4:115,375,484...115,390,846
Ensembl chr 4:115,375,461...115,390,846

G

cytochrome P450, family 4, subfamily a, polypeptide 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4A14 mRNA

NCBI chr 4:115,343,397...115,353,355
Ensembl chr 4:115,343,397...115,353,339

G

cytochrome P450, family 4, subfamily b, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4B1 mRNA

NCBI chr 4:115,481,895...115,504,918
Ensembl chr 4:115,481,922...115,504,920

G

cytochrome P450, family 4, subfamily f, polypeptide 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F13 mRNA

NCBI chr17:33,143,662...33,166,389
Ensembl chr17:33,143,662...33,166,376

G

cytochrome P450, family 4, subfamily f, polypeptide 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F14 mRNA

NCBI chr17:33,122,331...33,136,353
Ensembl chr17:33,124,044...33,136,316

G

cytochrome P450, family 4, subfamily f, polypeptide 17

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F17 mRNA

NCBI chr17:32,725,404...32,749,132
Ensembl chr17:32,725,024...32,749,117

G

cytochrome P450, family 4, subfamily f, polypeptide 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP4F39 mRNA

NCBI chr17:32,671,670...32,712,294
Ensembl chr17:32,671,697...32,712,294

G

cytochrome P450, family 4, subfamily f, polypeptide 40

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F40 mRNA

NCBI chr17:32,877,860...32,895,893
Ensembl chr17:32,877,874...32,895,888

G

cytochrome P450, family 7, subfamily a, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP7A1 mRNA

NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633

G

cytochrome P450, family 7, subfamily b, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP7B1 mRNA

NCBI chr 3:18,126,108...18,298,054
Ensembl chr 3:18,126,114...18,297,502

G

dihydrolipoamide branched chain transacylase E2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of DBT protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of DBT protein]

NCBI chr 3:116,306,776...116,343,630
Ensembl chr 3:116,306,719...116,343,630

G

decorin

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DCN mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DCN protein]

PMID:29950665 PMID:32272095

NCBI chr10:97,315,362...97,354,025
Ensembl chr10:97,315,471...97,354,005

G

discoidin domain receptor family, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DDR2 mRNA

NCBI chr 1:169,799,874...169,938,525
Ensembl chr 1:169,799,876...169,938,331

G

DEPP1 autophagy regulator

increases expression

Dextran Sulfate results in increased expression of DEPP1 mRNA

NCBI chr 6:116,627,645...116,629,808
Ensembl chr 6:116,627,570...116,629,755

G

Der1-like domain family, member 3

increases expression

Dextran Sulfate results in increased expression of DERL3 mRNA

NCBI chr10:75,729,232...75,731,775
Ensembl chr10:75,729,247...75,731,775

G

diacylglycerol kinase, beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DGKB mRNA

NCBI chr12:37,930,169...38,684,238
Ensembl chr12:37,867,725...38,684,238

G

diacylglycerol kinase, iota

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DGKI mRNA

NCBI chr 6:36,814,316...37,281,034
Ensembl chr 6:36,822,957...37,277,119

G

24-dehydrocholesterol reductase

decreases expression

Dextran Sulfate results in decreased expression of DHCR24 mRNA

NCBI chr 4:106,418,279...106,446,310
Ensembl chr 4:106,418,235...106,446,310

G

dehydrogenase/reductase 9

increases expression

Dextran Sulfate results in increased expression of DHRS9 mRNA

NCBI chr 2:69,210,806...69,233,430
Ensembl chr 2:69,210,789...69,234,877

G

dehydrogenase/reductase X linked

increases expression

Dextran Sulfate results in increased expression of DHRSX mRNA

NCBI chr 4:156,390,105...156,410,432

G

dickkopf WNT signaling pathway inhibitor 2

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA]

NCBI chr 3:131,791,027...131,886,065
Ensembl chr 3:131,791,053...131,886,065

G

delta like non-canonical Notch ligand 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DLK1 mRNA

NCBI chr12:109,418,411...109,429,262
Ensembl chr12:109,418,749...109,429,262

G

dystrophia myotonica-protein kinase

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of DMPK mRNA

NCBI chr 7:18,817,571...18,827,746
Ensembl chr 7:18,817,774...18,827,746

G

doublesex and mab-3 related transcription factor like family A1

decreases expression

Dextran Sulfate results in decreased expression of DMRTA1 mRNA

NCBI chr 4:89,576,435...89,583,003
Ensembl chr 4:89,567,673...89,583,009

G

dystrophia myotonica-containing WD repeat motif

increases expression

Dextran Sulfate results in increased expression of DMWD mRNA

NCBI chr 7:18,810,002...18,816,701
Ensembl chr 7:18,810,152...18,816,701

G

DnaJ heat shock protein family (Hsp40) member C10

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DNAJC10 protein]

NCBI chr 2:80,145,790...80,184,399
Ensembl chr 2:80,145,810...80,184,387

G

dynamin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM1 mRNA

NCBI chr 2:32,198,483...32,243,361
Ensembl chr 2:32,198,483...32,243,350

G

dynamin 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM3 mRNA

NCBI chr 1:161,810,022...162,305,890
Ensembl chr 1:161,810,022...162,305,603

G

docking protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DOK2 mRNA

NCBI chr14:71,003,336...71,015,934
Ensembl chr14:71,003,476...71,015,935

G

dipeptidase 1

multiple interactions
increases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP1 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DPEP1 protein]

PMID:32272095 PMID:35999755

NCBI chr 8:123,913,069...123,928,551
Ensembl chr 8:123,912,981...123,928,551

G

dipeptidase 2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DPEP2 mRNA

PMID:29950665 PMID:35999755

NCBI chr 8:106,711,577...106,732,658
Ensembl chr 8:106,711,576...106,718,391
Ensembl chr 8:106,711,576...106,718,391

G

dihydropyrimidine dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DPYD mRNA

NCBI chr 3:118,355,758...119,226,573
Ensembl chr 3:118,355,778...119,226,573

G

DR1 associated protein 1

increases expression

Dextran Sulfate results in increased expression of DRAP1 mRNA

NCBI chr19:5,472,832...5,475,007
Ensembl chr19:5,472,833...5,475,007

G

dopamine receptor D4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD4 mRNA

NCBI chr 7:140,871,931...140,874,868
Ensembl chr 7:140,871,919...140,876,377

G

dopamine receptor D5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD5 mRNA

NCBI chr 5:38,476,742...38,479,868
Ensembl chr 5:38,476,710...38,479,861

G

deltex 1, E3 ubiquitin ligase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DTX1 mRNA

NCBI chr 5:120,818,268...120,850,879
Ensembl chr 5:120,818,267...120,849,992

G

dual oxidase maturation factor 2

increases expression

Dextran Sulfate results in increased expression of DUOXA2 mRNA

NCBI chr 2:122,129,381...122,133,088
Ensembl chr 2:122,129,381...122,133,366

G

dual specificity phosphatase 1

multiple interactions
increases expression

DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]
Dextran Sulfate results in increased expression of DUSP1 mRNA

PMID:30844440 PMID:35093514

NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102

G

enoyl-Coenzyme A delta isomerase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ECI1 mRNA

NCBI chr17:24,645,657...24,658,290
Ensembl chr17:24,645,615...24,658,322

G

Ecm29 proteasome adaptor and scaffold

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ECPAS protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ECPAS protein]

NCBI chr 4:58,797,234...58,917,748
Ensembl chr 4:58,798,911...58,912,749

G

ectodysplasin-A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA mRNA

NCBI chr X:99,019,212...99,444,366
Ensembl chr X:99,019,212...99,444,368

G

ectodysplasin A2 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA2R mRNA

NCBI chr X:96,375,936...96,420,786
Ensembl chr X:96,377,446...96,420,822

G

endothelial differentiation-related factor 1

increases expression

Dextran Sulfate results in increased expression of EDF1 mRNA

NCBI chr 2:25,447,838...25,452,096
Ensembl chr 2:25,447,859...25,452,094

G

endothelin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDN1 mRNA

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

endothelin 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of EDN2 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EDN2 mRNA

PMID:16216902 PMID:29950665

NCBI chr 4:120,018,403...120,024,557
Ensembl chr 4:120,018,403...120,024,557

G

endothelin receptor type A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDNRA mRNA

NCBI chr 8:78,389,658...78,451,081
Ensembl chr 8:78,389,660...78,451,093

G

eukaryotic translation elongation factor 1 gamma

decreases expression

Dextran Sulfate results in decreased expression of EEF1G protein

NCBI chr19:8,944,405...8,955,544
Ensembl chr19:8,944,405...8,955,843

G

epidermal growth factor-containing fibulin-like extracellular matrix protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EFEMP2 mRNA

NCBI chr19:5,523,974...5,532,548
Ensembl chr19:5,523,982...5,532,545

G

EF hand domain containing 2

increases expression

Dextran Sulfate results in increased expression of EFHD2 mRNA

NCBI chr 4:141,585,453...141,602,231
Ensembl chr 4:141,585,453...141,602,231

G

ephrin A1

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of EFNA1 mRNA

NCBI chr 3:89,179,037...89,188,258
Ensembl chr 3:89,179,040...89,188,449

G

egl-9 family hypoxia-inducible factor 2

increases expression

Dextran Sulfate results in increased expression of EGLN2 mRNA

NCBI chr 7:26,858,083...26,866,227
Ensembl chr 7:26,858,083...26,866,227

G

EH-domain containing 1

decreases expression

Dextran Sulfate results in decreased expression of EHD1 protein

NCBI chr19:6,326,926...6,350,126
Ensembl chr19:6,326,755...6,350,126

G

EH-domain containing 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of EHD4 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of EHD4 protein

NCBI chr 2:119,919,958...119,985,028
Ensembl chr 2:119,919,656...119,985,087

G

enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EHHADH mRNA

NCBI chr16:21,580,035...21,606,589
Ensembl chr16:21,580,037...21,606,557

G

euchromatic histone lysine N-methyltransferase 2

increases expression

Dextran Sulfate results in increased expression of EHMT2 mRNA

NCBI chr17:35,117,427...35,133,049
Ensembl chr17:35,117,445...35,133,028

G

eukaryotic translation initiation factor 2-alpha kinase 2

multiple interactions
increases phosphorylation

EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of EIF2AK2 protein]

NCBI chr17:79,157,933...79,190,001
Ensembl chr17:79,159,993...79,190,002

G

eukaryotic translation initiation factor 3, subunit A

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of EIF3A mRNA

NCBI chr19:60,749,554...60,779,131
Ensembl chr19:60,749,555...60,779,096

G

eukaryotic translation initiation factor 5A

decreases expression

Dextran Sulfate results in decreased expression of EIF5A protein

NCBI chr11:69,807,538...69,812,784
Ensembl chr11:69,807,540...69,812,784

G

eukaryotic translation initiation factor 5B

increases expression

Dextran Sulfate results in increased expression of EIF5B mRNA

NCBI chr 1:38,037,091...38,094,660
Ensembl chr 1:38,037,091...38,094,660

G

elastase, neutrophil expressed

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELANE mRNA

NCBI chr10:79,722,146...79,724,050
Ensembl chr10:79,722,081...79,724,049

G

engulfment and cell motility 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELMO2 mRNA

NCBI chr 2:165,129,951...165,168,421
Ensembl chr 2:165,129,951...165,168,399

G

ER membrane protein complex subunit 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of EMC2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of EMC2 protein]

NCBI chr15:43,340,603...43,391,174
Ensembl chr15:43,340,625...43,391,159

G

epithelial membrane protein 2

decreases expression

Dextran Sulfate results in decreased expression of EMP2 mRNA

NCBI chr16:10,099,613...10,131,832
Ensembl chr16:10,099,613...10,131,832

G

endoglin

decreases expression

Dextran Sulfate results in decreased expression of ENG mRNA

NCBI chr 2:32,536,607...32,572,681
Ensembl chr 2:32,536,607...32,572,681

G

enolase 1, alpha non-neuron

decreases expression

Dextran Sulfate results in decreased expression of ENO1 protein

NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336
Ensembl chr18:150,321,178...150,333,336

G

enolase 3, beta muscle

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ENO3 protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of ENO3 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ENO3 protein]

PMID:32272095 PMID:35999755

NCBI chr11:70,543,973...70,553,339
Ensembl chr11:70,548,028...70,553,339

G

glutamyl aminopeptidase

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ENPEP protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ENPEP protein]

NCBI chr 3:129,062,826...129,126,398
Ensembl chr 3:129,062,824...129,126,369

G

ectonucleoside triphosphate diphosphohydrolase 5

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of ENTPD5 mRNA

NCBI chr12:84,420,649...84,455,803
Ensembl chr12:84,420,631...84,455,803

G

E1A binding protein p300

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EP300 mRNA

NCBI chr15:81,470,329...81,536,273
Ensembl chr15:81,469,552...81,536,278

G

epoxide hydrolase 1, microsomal

decreases expression

Dextran Sulfate results in decreased expression of EPHX1 mRNA

NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB2 mRNA

NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542

G

erb-b2 receptor tyrosine kinase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB3 mRNA

NCBI chr10:128,403,392...128,425,504
Ensembl chr10:128,403,392...128,425,521

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ERBB4 mRNA

NCBI chr 1:68,071,063...69,147,756
Ensembl chr 1:68,071,345...69,147,218

G

epiregulin

decreases response to substance
increases expression

EREG protein results in decreased susceptibility to Dextran Sulfate
dextran sodium sulfate increases expression of Ereg protein in colonic mucosa

CTD
RGD

PMID:15456865 PMID:20498653

NCBI chr 5:91,222,476...91,241,508
Ensembl chr 5:91,222,481...91,241,505

G

ERBB receptor feedback inhibitor 1

increases expression

Dextran Sulfate results in increased expression of ERRFI1 mRNA

NCBI chr 4:150,938,253...150,953,346
Ensembl chr 4:150,938,376...150,953,349

G

endothelial cell-specific adhesion molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESAM mRNA

NCBI chr 9:37,439,385...37,449,615
Ensembl chr 9:37,439,374...37,449,615

G

estrogen receptor 1 (alpha)

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ESR1 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESR1 mRNA

PMID:29950665 PMID:30270565

NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614

G

estrogen receptor 2 (beta)

multiple interactions

Dextran Sulfate promotes the reaction [Zearalenone results in increased expression of ESR2 mRNA]

NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033

G

Ena-vasodilator stimulated phosphoprotein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EVL mRNA

NCBI chr12:108,520,942...108,654,775
Ensembl chr12:108,520,979...108,654,775

G

Ewing sarcoma breakpoint region 1

increases expression

Dextran Sulfate results in increased expression of EWSR1 mRNA

NCBI chr11:5,019,687...5,049,314
Ensembl chr11:5,019,689...5,049,266

G

coagulation factor X

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F10 mRNA

NCBI chr 8:13,087,308...13,106,676
Ensembl chr 8:13,087,308...13,106,676

G

coagulation factor XI

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of F11 protein

NCBI chr 8:45,693,696...45,715,092
Ensembl chr 8:45,694,211...45,715,068

G

coagulation factor XIII, A1 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F13A1 mRNA

NCBI chr13:37,051,150...37,234,220
Ensembl chr13:37,051,152...37,234,220

G

coagulation factor II thrombin receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F2R mRNA

NCBI chr13:95,738,288...95,754,974
Ensembl chr13:95,738,311...95,754,995

G

F2R like trypsin receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of F2RL1 mRNA

NCBI chr13:95,648,226...95,661,748
Ensembl chr13:95,648,240...95,661,735

G

coagulation factor V

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F5 mRNA

NCBI chr 1:163,979,396...164,048,539
Ensembl chr 1:163,979,407...164,047,846

G

fatty acid amide hydrolase

multiple interactions

[Serotonin co-treated with Dextran Sulfate] results in decreased expression of FAAH protein

NCBI chr 4:115,853,866...115,876,034
Ensembl chr 4:115,824,342...115,875,123

G

fatty acid binding protein 4, adipocyte

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of FABP4 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FABP4 protein]

PMID:26271895 PMID:32272095

NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636

G

fatty acid binding protein 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FABP6 mRNA

NCBI chr11:43,486,867...43,492,389
Ensembl chr11:43,486,876...43,492,367

G

fatty acid desaturase 1

decreases expression

Dextran Sulfate results in decreased expression of FADS1 mRNA

NCBI chr19:10,160,245...10,174,238
Ensembl chr19:10,160,252...10,174,241

G

fatty acid desaturase 2

decreases expression

Dextran Sulfate results in decreased expression of FADS2 mRNA

NCBI chr19:10,040,129...10,078,867
Ensembl chr19:10,040,129...10,079,110

G

family with sequence similarity 229, member A

increases expression

Dextran Sulfate results in increased expression of FAM229A mRNA

NCBI chr 4:129,384,983...129,385,749
Ensembl chr 4:129,384,983...129,385,749

G

family with sequence similarity 50, member B

increases expression

Dextran Sulfate results in increased expression of FAM50B mRNA

NCBI chr13:34,918,833...34,931,605
Ensembl chr13:34,918,833...34,931,606

G

family with sequence similarity 98, member B

increases expression

Dextran Sulfate results in increased expression of FAM98B mRNA

NCBI chr 2:117,080,150...117,102,021
Ensembl chr 2:117,080,220...117,102,021

G

FAU ubiquitin like and ribosomal protein S30 fusion

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of FAU protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FAU protein]

NCBI chr19:6,107,977...6,109,554
Ensembl chr19:6,107,874...6,109,554

G

fibulin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN2 mRNA

NCBI chr 6:91,189,442...91,249,522
Ensembl chr 6:91,189,437...91,249,522

G

fibulin 5

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN5 mRNA
Dextran Sulfate results in decreased expression of FBLN5 mRNA

PMID:29950665 PMID:35093514

NCBI chr12:101,712,820...101,785,541
Ensembl chr12:101,712,824...101,785,314

G

fibrillin 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBN1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FBN1 protein]

PMID:29950665 PMID:32272095

NCBI chr 2:125,142,514...125,348,417
Ensembl chr 2:125,142,514...125,349,913

G

F-box protein 2

increases expression

Dextran Sulfate results in increased expression of FBXO2 mRNA

NCBI chr 4:148,244,605...148,250,874
Ensembl chr 4:148,245,078...148,250,881

G

Fc receptor, IgE, high affinity I, gamma polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCER1G mRNA

NCBI chr 1:171,057,141...171,061,918
Ensembl chr 1:171,057,141...171,061,934

G

Fc receptor, IgG, high affinity I

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR1 mRNA

NCBI chr 3:96,190,225...96,201,285
Ensembl chr 3:96,190,225...96,201,285

G

Fc receptor, IgG, low affinity IIb

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR2B mRNA

NCBI chr 1:170,786,186...170,804,141
Ensembl chr 1:170,786,186...170,804,116

G

Fc receptor, IgG, low affinity III

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR3 mRNA

NCBI chr 1:170,878,738...170,893,477
Ensembl chr 1:170,878,743...170,892,504

G

Fc receptor, IgG, low affinity IV

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR4 mRNA

NCBI chr 1:170,846,495...170,857,330
Ensembl chr 1:170,846,489...170,857,330

G

fucose kinase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FCSK mRNA

NCBI chr 8:111,609,088...111,629,120
Ensembl chr 8:111,609,088...111,629,120

G

ferredoxin 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FDX1 protein]

NCBI chr 9:51,854,323...51,874,902
Ensembl chr 9:51,854,606...51,874,856

G

ferredoxin reductase

decreases expression

Dextran Sulfate results in decreased expression of FDXR mRNA

NCBI chr11:115,158,850...115,167,925
Ensembl chr11:115,158,850...115,167,876

G

fermitin family member 3

multiple interactions
decreases expression
increases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FERMT3 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FERMT3 protein]
Dextran Sulfate results in decreased expression of FERMT3 protein

PMID:32272095 PMID:35999755

NCBI chr19:6,976,326...6,996,837
Ensembl chr19:6,976,326...6,996,837

G

free fatty acid receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR2 mRNA

NCBI chr 7:30,517,778...30,523,200
Ensembl chr 7:30,517,773...30,523,200

G

free fatty acid receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR4 mRNA

NCBI chr19:38,085,527...38,102,711
Ensembl chr19:38,085,519...38,102,711

G

fibroblast growth factor 15

multiple interactions

Dextran Sulfate results in increased expression of and results in increased secretion of FGF15 protein

NCBI chr 7:144,450,269...144,454,690
Ensembl chr 7:144,450,268...144,454,690

G

fibroblast growth factor 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF18 mRNA

NCBI chr11:33,066,970...33,097,400
Ensembl chr11:33,067,430...33,097,400

G

fibroblast growth factor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 mRNA

NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257

G

fibroblast growth factor 23

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF23 mRNA

NCBI chr 6:127,049,865...127,059,257
Ensembl chr 6:127,049,865...127,058,371

G

fibroblast growth factor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF8 mRNA

NCBI chr19:45,724,930...45,731,380
Ensembl chr19:45,725,237...45,731,354

G

fibroblast growth factor 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF9 mRNA

NCBI chr14:58,308,543...58,350,311
Ensembl chr14:58,308,004...58,350,177

G

fibroblast growth factor receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGFR1 mRNA

NCBI chr 8:26,008,808...26,067,819
Ensembl chr 8:26,003,670...26,065,734

G

fibroblast growth factor receptor 4

increases expression

Dextran Sulfate results in increased expression of FGFR4 mRNA

NCBI chr13:55,300,631...55,316,572
Ensembl chr13:55,300,453...55,316,572

G

fibrinogen-like protein 1

increases expression

Dextran Sulfate results in increased expression of FGL1 protein

NCBI chr 8:41,644,471...41,671,015
Ensembl chr 8:41,644,471...41,668,193

G

four and a half LIM domains 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FHL1 protein

NCBI chr X:55,776,569...55,838,704
Ensembl chr X:55,777,147...55,838,706

G

four and a half LIM domains 2

decreases expression

Dextran Sulfate results in decreased expression of FHL2 mRNA

NCBI chr 1:43,162,233...43,237,501
Ensembl chr 1:43,162,234...43,236,144

G

four and a half LIM domains 3

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FHL3 protein]

NCBI chr 4:124,589,750...124,602,404
Ensembl chr 4:124,594,494...124,602,404

G

filamin, alpha

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FLNA protein

NCBI chr X:73,267,067...73,293,787
Ensembl chr X:73,267,067...73,293,426

G

flotillin 2

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FLOT2 protein]

NCBI chr11:77,928,757...77,951,260
Ensembl chr11:77,928,757...77,951,260

G

FMS-like tyrosine kinase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT1 mRNA

NCBI chr 5:147,498,414...147,663,419
Ensembl chr 5:147,498,414...147,662,821

G

FMS-like tyrosine kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT4 mRNA

NCBI chr11:49,500,506...49,543,566
Ensembl chr11:49,500,090...49,543,566

G

flavin containing monooxygenase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMO1 mRNA

NCBI chr 1:162,657,130...162,694,170
Ensembl chr 1:162,657,130...162,694,179

G

fibromodulin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMOD mRNA

NCBI chr 1:133,964,992...133,976,018
Ensembl chr 1:133,964,992...133,976,015

G

fibronectin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FN1 mRNA

NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359

G

FBJ osteosarcoma oncogene

multiple interactions
increases expression

Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]; GRK6 mutant form promotes the reaction [Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]]
Dextran Sulfate results in increased expression of FOS mRNA

PMID:18687398 PMID:35093514

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

fos-like antigen 1

increases expression

Dextran Sulfate results in increased expression of FOSL1 protein

NCBI chr19:5,497,726...5,505,966
Ensembl chr19:5,497,575...5,505,974

G

forkhead box A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA2 mRNA

NCBI chr 2:147,884,797...147,888,889
Ensembl chr 2:147,884,797...147,888,889

G

forkhead box A3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA3 mRNA

NCBI chr 7:18,747,208...18,757,464
Ensembl chr 7:18,747,209...18,757,463

G

forkhead box O1

increases expression

Dextran Sulfate results in increased expression of FOXO1 mRNA; Dextran Sulfate results in increased expression of FOXO1 protein

NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642

G

forkhead box O3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXO3 mRNA

NCBI chr10:42,057,841...42,152,691
Ensembl chr10:42,057,837...42,152,751

G

forkhead box O4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FOXO4 mRNA

NCBI chr X:100,297,855...100,304,479
Ensembl chr X:100,298,134...100,304,479

G

forkhead box P3

increases methylation
increases expression
multiple interactions

Dextran Sulfate results in increased methylation of FOXP3 gene
Dextran Sulfate results in increased expression of FOXP3 mRNA
kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]
Chlorpyrifos inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased methylation of FOXP3 gene]

PMID:20881082 PMID:21858153 PMID:31807802 PMID:34998820

NCBI chr X:7,445,915...7,461,482
Ensembl chr X:7,439,883...7,461,484

G

fucose-1-phosphate guanylyltransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPGT mRNA

NCBI chr 3:154,790,552...154,799,024
Ensembl chr 3:154,790,555...154,799,040

G

formyl peptide receptor, related sequence 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of FPR-RS6 mRNA

NCBI chr17:20,402,340...20,403,359
Ensembl chr17:20,402,340...20,403,359

G

formyl peptide receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR1 mRNA

NCBI chr17:18,096,733...18,104,201
Ensembl chr17:18,096,733...18,104,202

G

formyl peptide receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR2 mRNA

NCBI chr17:18,108,086...18,114,214
Ensembl chr17:18,108,086...18,114,214

G

formyl peptide receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPR3 mRNA

NCBI chr17:18,190,720...18,191,939
Ensembl chr17:18,108,114...18,191,939

G

frequently rearranged in advanced T cell lymphomas 2

increases expression

Dextran Sulfate results in increased expression of FRAT2 mRNA

NCBI chr19:41,834,411...41,836,571
Ensembl chr19:41,834,411...41,836,571

G

follicle stimulating hormone beta

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of FSHB protein
gingerol inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein]

NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001

G

follicle stimulating hormone receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSHR mRNA

NCBI chr17:89,292,380...89,508,103
Ensembl chr17:89,292,380...89,508,103

G

follistatin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FST mRNA

NCBI chr13:114,588,798...114,595,522
Ensembl chr13:114,588,826...114,595,487

G

follistatin-like 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSTL3 mRNA

NCBI chr10:79,613,108...79,618,464
Ensembl chr10:79,613,106...79,618,464

G